Neos Therapeutics (NEOS) 10-K 18 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 15, 2016
Document and Entity Information
Entity Registrant Name	Neos Therapeutics, Inc.
Entity Central Index Key	1,467,652
Trading Symbol	neos
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float		$ 160.6
Entity Common Stock, Shares Outstanding		16,035,048
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 90,763	$ 13,343
Short term investments		3,000
Accounts receivable, net of allowances of $1,039 and $204, respectively	3,903	367
Inventories	2,520	2,031
Other current assets	1,058	264
Total current assets	98,244	19,005
Property and Equipment, net	5,124	5,831
Intangible Assets, net	16,672	18,167
Other Assets	2,470	2,227
Total assets	122,510	45,230
Current Liabilities:
Accounts payable	4,824	1,257
Accrued expenses	3,141	2,715
Current portion of long-term debt	7,973	1,653
Total current liabilities	15,938	5,625
Long-Term Liabilities:
Long-term debt, net of current portion	26,271	23,121
Earnout liability	214	756
Deferred gain on leaseback	547	1,383
Deferred rent	1,166	1,189
Warrant liabilities		1,789
Total long-term liabilities	$ 28,198	28,238
Redeemable Preferred Stock
Redeemable Preferred Stock, $0.001 par value		$ 90,149
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2015; no shares authorized, issued or outstanding at December 31, 2014
Common stock, $0.001 par value, 100,000,000 and 35,000,000 authorized at December 31, 2015 and December 31, 2014, respectively; 16,025,155 and 16,015,958 issued and outstanding, respectively, at December 31, 2015; 938,859 and 882,954 issued and outstanding at December 31, 2014, respectively	$ 16	$ 1
Treasury stock, at cost, 9,197 and 55,905 shares at December 31, 2015 and 2014, respectively	(171)
Additional paid-in capital	195,314	4,831
Accumulated deficit	(116,785)	(83,614)
Total stockholders' equity (deficit)	78,374	(78,782)
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	$ 122,510	45,230
Series A preferred stock
Redeemable Preferred Stock
Redeemable Preferred Stock, $0.001 par value		1,068
Series B preferred stock
Redeemable Preferred Stock
Redeemable Preferred Stock, $0.001 par value		14,559
Series B-1 preferred stock
Redeemable Preferred Stock
Redeemable Preferred Stock, $0.001 par value		32,391
Series C preferred stock
Redeemable Preferred Stock
Redeemable Preferred Stock, $0.001 par value		$ 42,131

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Receivables allowance (in dollars)	$ 1,039	$ 204
Redeemable preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized shares	5,000,000	0
Preferred Stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	100,000,000	35,000,000
Common stock, issued shares	16,025,155	938,859
Common stock, outstanding shares	16,015,958	882,954
Treasury Stock, Shares	9,197	55,905
Series A preferred stock
Redeemable preferred stock, authorized shares	0	1,170,000
Redeemable preferred stock, issued shares	0	1,170,000
Redeemable preferred stock, outstanding shares	0	1,170,000
Redeemable preferred stock, liquidation preference (in dollars)		$ 5,850
Series B preferred stock
Redeemable preferred stock, authorized shares	0	4,000,000
Redeemable preferred stock, issued shares	0	3,113,099
Redeemable preferred stock, outstanding shares	0	3,113,099
Redeemable preferred stock, liquidation preference (in dollars)		$ 15,565
Series B-1 preferred stock
Redeemable preferred stock, authorized shares	0	8,830,000
Redeemable preferred stock, issued shares	0	5,461,802
Redeemable preferred stock, outstanding shares	0	5,461,802
Redeemable preferred stock, liquidation preference (in dollars)		$ 61,647
Series C preferred stock
Redeemable preferred stock, authorized shares	0	13,500,000
Redeemable preferred stock, issued shares	0	8,753,547
Redeemable preferred stock, outstanding shares	0	8,753,547
Redeemable preferred stock, liquidation preference (in dollars)		$ 43,768

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Product	$ 3,792	$ 316
Manufacturing		113	$ 137
Profit sharing		169	226
Development		160	681
Net Sales	3,792	758	1,044
Cost of Goods Sold	5,547	3,354	2,534
Gross loss	(1,755)	(2,596)	(1,490)
Operating Expenses
Research and Development	11,887	10,601	9,974
Selling and marketing expenses	5,462	212	153
General and administrative expenses	7,474	5,063	5,471
Loss from operations	(26,578)	(18,472)	(17,088)
Interest Expense	(3,721)	(2,954)	(2,115)
Other Income, net	831	826	603
Change in fair value of earnout and warrant liabilities	(1,313)	(249)
Net loss from continuing operations	(30,781)	(20,849)	(18,600)
Loss from discontinued operations, including $544 of impairment charges in 2013			(437)
Net loss	(30,781)	(20,849)	(19,037)
Net loss from continuing operations attributable to common stock
Net loss from continuing operations	(30,781)	(20,849)	(18,600)
Preferred Stock Accretion to Redemption Value	(1,169)	(1,118)	(1,227)
Preferred Stock Dividends	(1,221)	(2,185)	(2,185)
Net loss from continuing operations attributable to common stock	(33,171)	(24,152)	(22,012)
Net loss attributable to common stock
Loss from discontinued operations, including $544 of impairment charges in 2013			(437)
Net loss	(30,781)	(20,849)	(19,037)
Preferred Stock Accretion to Redemption Value	(1,169)	(1,118)	(1,227)
Preferred Stock Dividends	(1,221)	(2,185)	(2,185)
Net loss attributable to common stock	$ (33,171)	$ (24,152)	$ (22,449)
Weighted average common shares outstanding
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	7,581,881	876,318	788,964
Net loss per share attributable to common stock, basic and diluted
Net loss per share from continuing operations attributable to common stock	$ (4.38)	$ (27.56)	$ (27.90)
Loss per share from discontinued operations			(0.55)
Net loss per share attributable to common stock	$ (4.38)	$ (27.56)	$ (28.45)

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (parenthetical)	12 Months Ended
	Dec. 31, 2013USD ($)
Loss from discontinued operations, including $545 of impairment charges in 2013
Discontinued operations, impairment charges	$ 544,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($) $ in Thousands	Common StockIPO	Common Stock	Treasury Stock.	Additional Paid-in CapitalIPO	Additional Paid-in Capital	Accumulated DeficitSeries B preferred stock	Accumulated DeficitSeries B-1 preferred stock	Accumulated DeficitSeries C preferred stock	Accumulated Deficit	Series B preferred stock	Series B-1 preferred stock	Series C preferred stock	IPO	Total
Balance, beginning at Dec. 31, 2012		$ 1			$ 4,514				$ (37,012)					$ (32,497)
Balance, beginning (in shares) at Dec. 31, 2012		770,412
Increase (Decrease) in Stockholders Equity
Restricted stock grants		149,244
Proceeds from exercise of options and warrants					2									2
Proceeds from exercise of options and warrants (in shares)		5,795
Share-based compensation expense					101									$ 101
Preferred Stock accretion to redemption value						$ (394)	$ (756)	$ (78)		$ (394)	$ (756)	$ (78)
Accrued dividend							(2,185)				(2,185)
Treasury shares purchased (in shares)			(55,905)											(55,905)
Net loss									(19,037)					$ (19,037)
Balance, ending at Dec. 31, 2013		$ 1			4,617				(59,462)					(54,844)
Balance, ending (in shares) at Dec. 31, 2013		925,451	(55,905)
Increase (Decrease) in Stockholders Equity
Proceeds from exercise of options and warrants					4									4
Proceeds from exercise of options and warrants (in shares)		13,408
Share-based compensation expense					210									210
Preferred Stock accretion to redemption value						(352)	(679)	(87)		(352)	(679)	(87)
Accrued dividend							(2,185)				(2,185)
Net loss									(20,849)					(20,849)
Balance, ending at Dec. 31, 2014		$ 1			4,831				(83,614)					(78,782)
Balance, ending (in shares) at Dec. 31, 2014		938,859	(55,905)
Increase (Decrease) in Stockholders Equity
Proceeds from exercise of options and warrants					75									75
Proceeds from exercise of options and warrants (in shares)		325,292
Share-based compensation expense					1,181									1,181
Cancellation of treasury stock		(55,905)	55,905
Preferred Stock accretion to redemption value						$ (192)	(370)	$ (607)		$ (192)	(370)	$ (607)
Accrued dividend							$ (1,221)				$ (1,221)
Conversion of Redeemable Preferred Stock		$ 9			110,767									110,776
Conversion of Redeemable Preferred Stock (in shares)		9,217,983
Cashless exercise of Series C warrants issued with Series C financing					2,842									2,842
Cashless exercise of Series C warrants issued with Series C financing (in shares)		78,926
Reclassification of Series C warrants issued with senior debt					611									611
Net proceeds from issuance of common stock	$ 6			$ 75,007									$ 75,013
Net proceeds from issuance of common stock (in shares)	5,520,000
Purchase of treasury stock			$ (171)											(171)
Treasury shares purchased (in shares)			(9,197)
Net loss									(30,781)					(30,781)
Balance, ending at Dec. 31, 2015		$ 16	$ (171)		$ 195,314				$ (116,785)					$ 78,374
Balance, ending (in shares) at Dec. 31, 2015		16,025,155	(9,197)

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (30,781)	$ (20,849)	$ (19,037)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	1,724	1,645	1,330
Amortization of intangible assets	1,495	1,037	842
Changes in fair value of warrant and earnout liabilities	1,313	249
Amortization of patents	23	31
Amortization and write-off of senior debt fees	576	627	141
Gain on sale of equipment	(831)	(824)	(601)
Provision for bad debts		(264)	227
Loss on impairment of intangible assets			544
Share-based compensation expense	1,181	210	101
Interest accrued on note payable	548	511	592
Change in deferred rent	(23)	41	385
Changes in operating assets and liabilities:
Accounts receivable	(3,536)	417	971
Inventories	(489)	(1,612)	637
Other current assets	(794)	(167)	(97)
Other assets	(266)	(231)	(343)
Accounts payable	3,567	284	(349)
Accrued expenses	426	1,505	(298)
Net cash used in operating activities	(25,867)	(17,390)	(14,955)
Cash Flows From Investing Activities:
Net proceeds from sale of short-term investments	3,000	4,497	(7,498)
Capital expenditures	(1,023)	(339)	(2,019)
Intangible asset acquisition		(6,283)
Net cash provided by (used in) investing activities	1,977	(2,125)	(9,517)
Cash Flows from Financing Activities:
Proceeds from senior debt note	10,000	15,000
Proceeds from sale of equipment		795	5,500
Net proceeds from issuance of stock	18,122	17,350	8,523
Net proceeds from initial public offering, net of underwriting discounts, commissions and offering costs	75,013
Payments made on borrowings	(1,654)	(11,671)	(890)
Payments made to purchase treasury stock	(171)
Deferred financing costs		(563)
Net cash provided by financing activities	101,310	20,911	13,133
Increase (decrease) in cash and cash equivalents	77,420	1,396	(11,339)
Cash and Cash Equivalents:
Beginning	13,343	11,947	23,286
Ending	90,763	13,343	11,947
Noncash Investing and Financing Activities:
Earout liability incurred in connection with intangible assets acquisition		589
Issuance of stock warrants	2,131	1,707
Exercise of Series c warrants for Series C Preferred Stock	2,322
Cashless exercise of Series C warrants from Series C financing in IPO closing	2,842
Conversion of Redeemable Preferred Stocks into Common Stock	110,776
Reclassification of Series C warrants issued with senior debt upon IPO closing	611
Preferred Stock Accretion	1,169	1,118	1,227
Preferred Stock Dividend	1,221	2,185	2,185
Supplemental Cash Flow Information:
Interest paid	$ 2,524	$ 1,793	$ 1,324

Basis of presentation

Basis of presentation	12 Months Ended
	Dec. 31, 2015
Basis of presentation
Basis of presentation	Note 1. Basis of presentation The consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States of America, or GAAP, and with the rules and regulations of the Securities and Exchange Commission, or SEC.

Organization and nature of oper

Organization and nature of operations	12 Months Ended
	Dec. 31, 2015
Organization and nature of operations
Organization and nature of operations	Note 2. Organization and nature of operations Neos Therapeutics, Inc., a Delaware corporation, and its subsidiaries (the "Company") is a fully integrated pharmaceutical company. The Company has developed a broad, proprietary modified-release drug delivery technology that enables the manufacture of single and multiple ingredient extended-release pharmaceuticals in patient- and caregiver-friendly orally disintegrating tablet and liquid suspension dosage forms. The Company has a pipeline of extended-release pharmaceuticals including one approved product and two proprietary product candidates in late stage development for the treatment of attention deficit hyperactivity disorder ("ADHD"). Adzenys XR-ODT was approved by the US Food and Drug Administration, or FDA, on January 27, 2016. In addition, the Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) ("generic Tussionex") extended-release liquid suspension for the treatment of cough and upper respiratory symptoms of a cold. These products are developed and manufactured using the Company's proprietary and patented modified-release drug delivery technology. The Company's predecessor company was incorporated in Texas on November 30, 1994 as PharmaFab, Inc. and subsequently changed its name to Neostx, Inc. On June 15, 2009, the Company completed a reorganization pursuant to which substantially all of the capital stock of Neostx, Inc. was acquired by a newly formed Delaware corporation, named Neos Therapeutics, Inc. The remaining capital stock of Neostx, Inc. was acquired by the Company on June 29, 2015. Historically, the Company was primarily engaged in the development and contract manufacturing of unapproved or Drug Efficacy Study Indication ("DESI"), pharmaceuticals and, to a lesser extent, nutraceuticals for third parties. The unapproved or DESI pharmaceuticals contract business was discontinued in 2007 and the manufacturing of nutraceuticals for third parties was discontinued in March 2013. On August 28, 2014, the Company completed an acquisition of all of the rights to the Tussionex Abbreviated New Drug Application ("Tussionex ANDA"), which included the rights to produce, develop, market and sell, as well as all the profits from such selling activities, the Company's generic Tussionex, which the Company previously owned the rights to manufacture, but which was marketed and sold by the generic drug division of Cornerstone Biopharma, Inc. ("Cornerstone"). These rights were acquired from the collaboration of the Company, Cornerstone and Coating Place, Inc. ("CPI"), a supplier of the resins for the product (see Note 9). Prior to the acquisition, the Company, Cornerstone and CPI shared profits generated by the sale and manufacture of the product under a development and manufacturing agreement with those companies. On July 28, 2015, the Company closed its initial public offering ("IPO") whereby the Company sold 5,520,000 shares of common stock, at a public offering price of $15.00 per share, which includes 720,000 shares of common stock resulting from the underwriters' exercise of their over-allotment option at the IPO price on July 23, 2015. Proceeds from the Company's IPO, net of underwriting discounts and commissions and other offering costs, were $75.0 million. In connection with the IPO, the Company's Board of Directors approved a 1-for-2.4 reverse stock split of the Company's common stock which also resulted in a proportional adjustment to the conversion ratios of the preferred stock and the preferred stock warrants. All references to common stock and per share amounts in these condensed financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split. Between June 30, 2015 and July 27, 2015, the Company issued a total of 1,000,000 shares of its Series C redeemable convertible preferred stock ("Series C") to several existing investors upon the exercise of warrants to purchase Series C preferred stock ("Series C warrants") held by those investors at an exercise price of $5.00 per share, for an aggregate exercise price of $5.0 million. On the IPO closing date, all outstanding shares of redeemable preferred stock converted into 9,217,983 shares of common stock and all remaining outstanding Series C warrants issued in conjunction with purchases of Series C were net exercised at the IPO price for 78,926 shares of common stock. Upon the closing of the Company's IPO, all of the shares of the Company's redeemable convertible preferred stock ("Preferred Shares") were retired and cancelled and shall not be reissued as shares of such series, and all rights and preferences of those Preferred Shares were cancelled including the right to receive undeclared accumulated dividends. These transactions produced a significant increase in the number of shares outstanding which will impact the year-over-year comparability of the Company's loss per share calculations. Additionally, in connection with the closing of the IPO, the Company amended and restated its certificate of incorporation to increase the number of authorized shares of common stock to 100,000,000 and to authorize 5,000,000 shares of undesignated preferred stock.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2015
Summary of significant accounting policies
Summary of significant accounting policies	Note 3. Summary of significant accounting policies Principles of consolidation: At December 31, 2015, the consolidated financial statements include the accounts of the Company and its four wholly-owned subsidiaries. At December 31, 2014, Neos Therapeutics, Inc. owned, directly or indirectly, 100% of two of its subsidiaries and 99.9% of the third subsidiary, Neostx, Inc. ("NTX"). The remaining 0.1% ownership of NTX was held by a third party and all such remaining capital stock was acquired by the Company on June 29, 2015, and NTX was merged with and into the Company. The amounts attributable to the noncontrolling interest were not material to the consolidated financial statements. On September 16, 2015, the Company established two new wholly-owned subsidiaries, Neos Therapeutics Brands, LLC and Neos Therapeutics Commercial, LLC. All significant intercompany transactions have been eliminated. Cash equivalents: The Company invests its available cash balances in bank deposits and money market funds. The Company considers highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company's primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. Short-term investments: Short-term investments consist of U.S. Treasury Bills that have original maturities greater than three months but less than or equal to one year and are classified as available-for-sale securities. These investments are recorded at fair value. Realized gains and losses are reported in the consolidated statements of operations. Unrealized gains and losses are immaterial. Allowance for doubtful accounts: The allowance for doubtful accounts is maintained at a level considered adequate to provide for losses that can be reasonably anticipated. Management determines the adequacy of the allowance based on reviews of individual accounts, historical losses, existing economic conditions and estimates based on management's judgments in specific matters. Accounts are written off as they are deemed uncollectible based on periodic review of the accounts. There is no allowance for doubtful accounts at December 31, 2015 or December 31, 2014, as management believes that all receivables are fully collectible. Fair value of financial instruments: The carrying value of the Company's financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, other current assets, accounts payable, accrued expenses, and debt, approximates fair value due to the short-term nature of the instruments and/or the current interest rates payable in relation to current market conditions. The fair value of the Company's warrants and earnout liabilities is disclosed in Note 5. Inventories: Inventories, comprised of raw materials, labor, and manufacturing overhead, as well as finished goods inventory, are stated at the lower of cost (actual, which approximates first-in, first-out) or market, net of an allowance for obsolete inventory. Property and equipment: Property and equipment is recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the respective lease term or the estimated useful lives of the assets. Intangible assets: Intangible assets subject to amortization, which principally include proprietary modified-release drug delivery technology and the costs to acquire the rights to Tussionex ANDA, are recorded at cost and amortized over the estimated lives of the assets ranging from 10 to 20 years. Impairment of long-lived assets: Long-lived assets such as property and equipment and intangibles subject to amortization are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable. Such assets are also evaluated for impairment in light of the Company's continuing losses. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment charges were recorded for the years ended December 31, 2015 or December 31, 2014. Impairment charges of intangible assets related to the discontinued nutraceutical manufacturing operations of $544,000 were recognized in the year ended December 31, 2013. Patent costs: The Company estimates that the patents it has filed have a future beneficial value. Therefore, costs associated with filing for its patents are capitalized. Once the patent is approved and commercial revenue realized, the costs associated with the patent are amortized over the useful life of the patent. If the patent is not approved, the costs will be expensed. Revenue recognition: Revenue is generated from product sales, recorded on a net sales basis, and historically, manufacturing, development and profit sharing from a development and manufacturing agreement. Product revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed and determinable; and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid for the product, or the buyer is obligated to pay for the product and the obligation is not contingent on resale of the product, (3) the buyer's obligation to pay would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. The Company sells its generic Tussionex to a limited number of pharmaceutical wholesalers. Pharmaceutical wholesalers buy drug products directly from manufacturers. Title to the product passes upon delivery to the wholesalers, when the risks and rewards of ownership are assumed by the wholesaler (freight on board destination). These wholesalers then resell the product to retail customers such as food, drug and mass merchandisers. The Company's manufacturing, profit sharing and development revenue ended in 2014 as the Company has terminated the Company's development and manufacturing agreement. As a result of the Company's acquisition of the rights to commercialize and derive future profits from the Tussionex ANDA, the Company will utilize its manufacturing capability to derive revenue directly from sales made by the Company, rather than through the Company's commercial partner. Net product sales Net product sales for the Company's generic Tussionex product represent total gross product sales less gross to net sales adjustments. Gross to net sales adjustments include wholesaler fees and estimated allowances for product returns, government rebates, chargebacks and prompt-payment discounts to be incurred on the selling price of the respective product sales. Wholesale distribution fees are incurred on the management of these products by wholesalers and are recorded within net product sales based on definitive contractual agreements. The Company estimates gross to net sales adjustments for allowances for product returns, government rebates and chargebacks based upon analysis of third-party information, including information obtained from the Company's third party logistics provider, or 3PL, with respect to their inventory levels and sell-through to the wholesalers' customers, data available from third parties regarding prescriptions written for the Company's products, as well as actual experience as reported by the Company's customers and previous commercialization partners. Due to estimates and assumptions inherent in determining the amount of returns, rebates and chargebacks, the actual amount of returns and claims for rebates and chargebacks may be different from the estimates, at which time reserves would be adjusted accordingly. Allowances and accruals are recorded in the same period that the related revenue is recognized. Product returns Wholesalers' contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. Generic Tussionex product returns are estimated based upon data available from sales of the Company's product by its previous commercialization partner and from actual experience as reported by retailers. Historical trend of returns will be continually monitored and may result in future adjustments to such estimates. On August 26, 2014, the U.S. Drug Enforcement Agency reclassified the Company's generic Tussionex from a Schedule III controlled substance to a Schedule II controlled substance which had the effect of requiring unsold product at the wholesalers and the 3PL to either be relabeled or returned. This new ruling was effective October 6, 2014. As such, the Company established reserves for the estimated returns of such product outstanding at the wholesalers as of October 6, 2014. The Company had no inventory labeled as Schedule III at the 3PL as of the effective date. Medicaid rebates The Company's products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Estimated rebates payable under governmental programs, including Medicaid, are recorded as a reduction of revenue at the time revenues are recorded. For generic Tussionex, calculations related to these rebate accruals are estimated based on sales of the Company's product by its previous commercialization partner. Historical trend of Medicaid rebates will be continually monitored and may result in future adjustments to such estimates. Wholesaler Chargebacks The Company's products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company. Chargebacks are accounted for by establishing an accrual in an amount equal to the Company's estimate of chargeback claims at the time of product sale based on information provided by the distributor. Due to estimates and assumptions inherent in determining the amount of chargebacks, the actual amount of claims for chargebacks may be different from estimates, which may result in adjustments to such reserves. Manufacturing Manufacturing revenue is derived from product manufactured by the Company and sold by the Company's commercial partner under a development and manufacturing agreement. Manufacturing revenue is derived from a contractual supply price paid to the Company by the Company's commercial partners. Profit sharing Profit sharing revenue is recorded as the product is sold by the Company's commercial partner. The profit share is the Company's share of the net profits after taking into account net revenue, which is gross product sales by the Company's commercial partner, net of discounts, returns and allowances incurred by the Company's commercial partner, less collaboration expenses. Development revenue Development revenue from the development and manufacturing agreement has been recognized as the related services are completed. Development revenue in the form of milestone payments is recognized upon achievement of the related milestones and provided that collectability is reasonably assured and other revenue recognition criteria are met. Amounts received under cost reimbursement arrangements for production and research and development are recorded as offsets to the costs incurred and not recognized as revenue. Distribution expenses: Costs invoiced to the Company by its third party logistics firm are classified as cost of goods sold in the consolidated statements of operations. Shipping and handling costs: Amounts billed to customers for shipping and handling fees for the delivery of goods are classified as cost of goods sold in the consolidated statements of operations. Research and development costs: Research and development costs are charged to operations when incurred, include salaries and benefits, facilities costs, overhead costs, clinical trial costs, contract services, fees paid to regulatory authorities for review and approval of the Company's product candidates and other related costs, and are included in research and development in the consolidated statements of operations. Income taxes: Income taxes are accounted for using the liability method, under which deferred taxes are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax laws that will be in effect when the differences are expected to reverse. Management evaluates the Company's tax positions in accordance with guidance on accounting for uncertainty in income taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not that the position will be sustained upon examination. As of December 31, 2015 and December 31, 2014, the Company had no uncertain tax positions that qualify for recognition in the consolidated financial statements. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. Warrants: The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company's balance sheet at their fair value on the date of issuance and prior to completion of the Company's IPO were revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company estimates the fair value of its derivative liabilities using third party valuation analysis that utilizes option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. Prior to the closing of the IPO, the Company's Series C warrants were determined to be derivative liabilities and they were revalued at each subsequent balance sheet date. Upon closing the IPO, the warrants issued in conjunction with the Series C financing were exchanged in a cashless exercise for 947,185 shares of Series C which converted into 78,926 shares of the Company's common stock. The remaining Series C warrants issued with the senior debt to purchase 170,000 pre-split shares of Series C ("Hercules Warrants") were converted into warrants to purchase 70,833 shares of the Company's common stock and the warrant liability was reclassified to Additional Paid in Capital within Stockholders' Equity (Deficit). Share-based compensation: Share-based compensation awards, including grants of stock options to employees and directors and restricted stock and modifications to existing stock options, are recognized in the statement of operations based on their fair values. Compensation expense related to awards to employees is recognized on a straight-line basis, based on the grant date fair value, over the requisite service period of the award, which is generally the vesting term. The fair value of the Company's stock-based awards to employees and directors is estimated using the Black-Scholes option pricing model, which requires the input of and subjective assumptions, including (1) the expected stock price volatility, (2) the expected term of the award, (3) the risk-free interest rate and (4) expected dividends. Due to the previous lack of a public market for the trading of its common stock and a lack of company-specific historical and implied volatility data, prior to the IPO, the Company utilized third party valuation analyses to determine the fair value. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the actual expense recognized over the vesting period will only be for those options that vest. Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. Concentration of credit risk: Accounts receivable subjects the Company to concentrations of credit risk. Four customers accounted for all the revenue in the year ended December 31, 2015 and two customers accounted for substantially all revenue in each of the years ended December 31, 2014 and 2013. Accounts receivable at December 31, 2015 and 2014 were due from three customers and one customer, respectively. Segment information: Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development, manufacturing and commercialization of pharmaceuticals. Liquidity: During 2015, 2014 and 2013, the Company produced operating losses and used cash to fund operations. Management intends to achieve profitability through revenue growth from pharmaceutical products developed with its extended-release technologies. The Company does not anticipate it will be profitable until after the launch of its approved product, Adzenys XR-ODT, or one or more of its ADHD product candidates. With the completion of the Company's IPO in July 2015, management believes the Company presently has sufficient liquidity to continue to operate for at least the next 12 months. Application of revised accounting standards: In April 2012, the Jumpstart Our Business Startups Act (the "JOBS Act"), was enacted in the United States. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period and, as a result, will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. Recent accounting pronouncements: In April 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update, ("ASU"), No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (topic 360); Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides additional requirements to classify a disposal of a component of an entity or a group of components of an entity in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company adopted this guidance in the first quarter of 2015, and the adoption of this standard did not have a material impact on the Company's financial statements. In May 2014, the FASB issued ASU, No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2018. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect the adoption of this standard will have a material impact on the Company's financial statements. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This ASU is for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company has performed the review required by this ASU and believes the Company presently has sufficient liquidity to continue to operate into the first quarter of 2016. On April 7, 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest—Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by this ASU. This ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The Company elected to early adopt this standard which did not have a material impact on the Company's financial position or results of operations. In July 2015, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2015-11, Inventory—Simplifying the Measurement of Inventory (Topic 330). The amendments in this ASU require an entity to measure inventory that is not measured using the last-in, first-out (LIFO) or retail inventory methods at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company is evaluating this ASU and has not determined the effect of this standard on its ongoing financial reporting. In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842) . Under the new guidance, lessees will be required recognize the following for all leases (with the exception of short-term leases) at the commencement date: 1) A lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and 2) A right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company is evaluating this ASU and has not determined the effect of this standard on its ongoing financial reporting. From time to time, additional new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Reclassifications: Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current period's presentation. Subsequent events: The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

Net loss per share

Net loss per share	12 Months Ended
	Dec. 31, 2015
Net loss per share
Net loss per share	Note 4. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities, which include redeemable convertible preferred stock, warrants, and outstanding stock options under the stock option plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company's net loss position. The following potentially dilutive securities were excluded from consideration in the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: December 31, 2015 2014 2013 Series A Redeemable Convertible Preferred Stock (as converted) — Series B Redeemable Convertible Preferred Stock (as converted) — Series B-1 Redeemable Convertible Preferred Stock (as converted) — Series C Redeemable Convertible Preferred Stock (as converted) — Series C Redeemable Convertible Preferred Stock Warrants (as converted) — Common Stock Warrants Stock options

Fair value of financial instrum

Fair value of financial instruments	12 Months Ended
	Dec. 31, 2015
Fair value of financial instruments
Fair value of financial instruments	Note 5. Fair value of financial instruments Financial instruments are categorized into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the categorization of the financial instrument is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company's consolidated balance sheets are categorized as follows: Level 1: Unadjusted quoted prices for identical assets in an active market. Level 2: Quoted prices in markets that are not active or inputs that are observable either directly or indirectly for substantially the full-term of the asset. Level 2 inputs include the following: d Quoted prices for similar assets in active markets. d Quoted prices for identical or similar assets in nonactive markets. d Inputs other than quoted market prices that are observable. d Inputs that are derived principally from or corroborated by observable market data through correlation or other means. Level 3: Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. They reflect management's own assumptions about the assumptions a market participant would use in pricing the asset. The following table presents the hierarchy for the Company's financial instruments measured at fair value on a recurring basis for the indicated dates: Fair Value as of December 31, 2015 Level 1 Level 2 Level 3 Total (in thousands) Cash and cash equivalents $ $ — $ — $ Earnout liability — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value as of December 31, 2014 (in thousands) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ $ — $ — $ Short term investments — — Earnout liability — — Series C Redeemable Preferred Stock Warrants — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The Company's Level 1 assets include bank deposits, U.S. Treasury bills and money market funds with quoted prices in active markets. Level 3 liabilities include the fair values of the earnout liability and the outstanding warrants to purchase Series C. There were no outstanding warrants to purchase preferred stock as of December 31, 2015. Various methodologies were utilized to value the Level 3 liabilities including Black-Scholes-Merton, Probability-Weighted Expected Return ("PWERM"), Option Pricing and Monte Carlo. The methodologies and significant inputs used in the determination of the fair value of the Hercules Warrants were as follows: Series C Warrants Issued With March 28, 2014 Senior Debt Series C Warrants Issued With September 25, 2014 Senior Debt Revalue Series C Warrants Issued with Senior Debt at December 31, 2014 Revalue Series C Warrants Issued with Senior Debt at July 22, 2015 (Dollars in thousands, except $5 and $12 Exercise Prices) Date of Valuation 3/28/2014 9/25/2014 12/31/2014 7/22/2015 Valuation Method Black-Scholes-Merton PWERM and Black-Scholes-Merton PWERM and Option Pricing Black-Scholes-Merton Option-Pricing Dividend yield (per share) 0 0 0 0 Exercise price $5 $5 $5 $12 Volatility (annual) 60% 60% 60% 60% Risk-free rate (annual) 0.34% 2.03% .25% - 2.47% 1.78% Contractual term (years) 1.76 5.76 1 - 5 5 Number of warrants 60,000 110,000 170,000 70,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $124 $248 $454 $611 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As the Hercules Warrants converted into warrants for common stock effective on July 22, 2015 with the IPO, with a term of five years from the IPO date, it was determined that the Black-Scholes-Merton Option-Pricing model would provide a better indication of the fair value as it was designed to calculate the value of a put or call option over time. The methodologies and significant inputs used in the determination of the fair value of the Series C warrants issued with the Series C were as follows: Initial Valuation of December 31, 2014 Warrants Issued With Series C Redeemable Preferred Stock Initial Valuation of January 2015 Warrants Issued With Series C Redeemable Preferred Stock Initial Valuation of February 2015 Warrants Issued With Series C Redeemable Preferred Stock Revalue All Warrants Issued With Series C Redeemable Preferred Stock at July 22, 2015 (Dollars in thousands, except $5 and $12 Exercise Prices) Date of Valuation 12/31/2014 1/31/2015 2/28/2015 7/22/2015 Valuation Method PWERM and Option Pricing PWERM and Option Pricing PWERM and Option Pricing Intrinsic Value Dividend yield (per share) 0 0 0 0 Exercise price $5 $5 $5 $12 Volatility (annual) 60% 60% 60% — Risk-free rate (annual) .25% - 2.47% .25% - 2.47% .25% - 2.47% — Contractual term (years) 1 - 5 1 - 5 1 - 5 — Number of warrants 749,967 590,906 606,312 1,347,185 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $1,335 $1,052 $1,079 $4,042 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The methodologies and significant inputs used in the determination of the fair value of the earnout liability were as follows: Initial Valuation Earnout Liability December 31, 2014 Earnout Liability December 31, 2015 Earnout Liability (Dollars in thousands) Date of Valuation 8/28/2014 12/31/2014 12/31/2015 Valuation Method Monte Carlo Monte Carlo Monte Carlo Volatility (annual) 50% 50% 50% Risk-free rate (annual) .03% - 3.56% .15% - 3.21% .56% - 3.31% Time period from valuation until end of earnout .1708 - 9.8417 .5 - 9.5 .5 - 9.5 Earnout Target 1 $13,700 $13,700 $13,700 Earnout Target 2 $18,200 $18,200 $18,200 Discount rate 8.03% - 10.51% 7.96% - 11.03% 8.11% - 10.86% ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $589 $756 $214 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Significant changes to these assumptions in the preceding valuation tables would result in increases/decreases to the fair value of the outstanding Series C warrants and the earnout liability. Changes in Level 3 liabilities measured at fair value for the periods indicated were as follows: Earnout Liability Series C Warrants Issued With Senior Debt Series C Warrants Issued With Series C Redeemable Preferred Stock Financing (in thousands) Balance at December 31, 2013 $ — $ — $ — Additions during the period Changes in fair value — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2014 $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additions during the period — — Changes in fair value ) Warrants exercised — — ) Cashless warrant exercise due to IPO — — ) Conversion to common stock warrant — ) — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2015 $ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The reductions in fair value of the earnout liability shown above resulted from new information regarding the projected impact of the DEA's reclassification of Tussionex from a Schedule III controlled substance to a Schedule II controlled substance and a review of the launch dates of the Company's approved product, Adzenys XR-ODT, and its two ADHD product candidates. The increases in the fair value of the Series C warrants were due to the increased weighting of the IPO scenario in the PWERM model.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventories
Inventories	Note 6. Inventories Inventories at the indicated dates consist of the following: December 31, 2015 2014 (in thousands) Raw materials $ $ Work in progress Finished goods ​ ​ ​ ​ ​ ​ ​ ​ Inventory at cost Inventory reserve ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2015
Property and equipment
Property and equipment	Note 7. Property and equipment Property and equipment, net at the indicated dates consists of the following: December 31, 2015 2014 (in thousands) Assets under capital lease $ $ Leasehold improvements Manufacturing, packaging and lab equipment Office furniture and equipment Assets under construction ​ ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation and amortization (including $3,684 and $2,317 at December 31, 2015 and 2014, respectively, applicable to capital leases) ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization expense related to property and equipment was $1,724,000, $1,645,000 and $1,330,000 for the years ended December 31, 2015, 2014 and 2013, respectively. Depreciation and amortization expense is recorded in cost of goods sold, research and development, or general and administrative expenses in the accompanying consolidated statements of operations. As noted in Note 8, the Company sold and leased back a substantial portion of its operating assets in a series of capital lease transactions. Included in the total of assets under capital lease as of December 31, 2015 and December 31, 2014, are certain manufacturing, packaging and lab equipment that are temporarily idle as a result of the cessation of contract manufacturing. The cost of these assets was $1,699,000 and $1,728,000, and the accumulated depreciation of these assets was $1,396,000 and $925,000 at December 31, 2015 and December 31, 2014, respectively.

Sale-leaseback transaction

Sale-leaseback transaction	12 Months Ended
	Dec. 31, 2015
Sale-leaseback transaction
Sale-leaseback transaction	Note 8. Sale-leaseback transaction In 2012, the Company negotiated financing arrangements with a related party which provided for the sale-leaseback of up to $6.5 million of the Company's property and equipment with a bargain purchase option at the end of the respective lease. The transactions are accounted for as capital leases under the provisions of Accounting Standards Codification ("ASC") Topic 840-40, Leases—Sale Leaseback Transactions . Accordingly, the leased assets are recorded in property and equipment and the capitalized lease obligations are included in long-term liabilities at the present value of the future lease payments in accordance with the terms of each lease (see Note 12 for further details). Lease payments are applied using the effective interest rate inherent in each lease. Depreciation of the property and equipment is included within depreciation and amortization in the consolidated statements of operations and consolidated statements of cash flows. The financing arrangements referred to in the preceding paragraph were executed in five separate tranches that occurred in February, July and November 2013, and March 2014. In the aggregate, the Company sold groups of assets for $795,000 and $5.5 million, which resulted in a net gains of approximately $116,000 and $2.7 million, in the years ended December 31, 2014 and December 31, 2013, respectively, and executed capital leases for these assets with repurchase options at the end of each respective lease term. Gains on the transactions are recognized on a straight-line basis over each respective 42-month lease term. For the years ended December 31, 2015, 2014 and 2013 approximately $831,000, $824,000 and $601,000, respectively, of the net gain was recognized in other income on the consolidated statements of operations A summary of the sale-leaseback transactions are as follows: Leases 1 & 2 February 2013 Lease 3 July 2013 Lease 4 November 2013 Lease 5 March 2014 Total (in thousands) Capitalization of leased assets $ $ $ $ — $ 2013 Amortization ) ) ) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2013 — 2014 Capitalization of leased assets Assets retired in 2014 ) — — — ) 2014 Amortization ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2014 $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets retired in 2015 ) — ) — ) 2015 Amortization ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2015 $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2015
Intangible assets, net
Intangible assets, net	Note 9. Intangible assets Intangible assets, net at the indicated dates consist of the following: December 31, 2015 2014 (in thousands) Proprietary modified-release drug delivery technology $ $ Tussionex ANDA CPI profit sharing Other ​ ​ ​ ​ ​ ​ ​ ​ Accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As part of the June 15, 2009 reorganization of the Company as Neos Therapeutics, Inc., the Company performed a purchase price allocation analysis. The proprietary modified-release drug delivery technology was valued at $15.6 million based on projected cash flows expected to be generated from this technology. The $15.6 million is being amortized over 20 years. Amortization expense of $780,000 was recorded in each of the years ended December 31, 2015, 2014 and 2013. On August 28, 2014, the Company completed an acquisition of the rights to Tussionex ANDA from Cornerstone and CPI which was accounted for as an asset acquisition. Prior to the acquisition, the Company, Cornerstone and CPI shared profits generated by the sale and manufacture of the product under a development and manufacturing agreement, and Cornerstone had commercialization rights to the product. The Company paid $4.2 million to Cornerstone to buy out their rights to commercialize and derive future profits from the product and entered into an agreement whereby Cornerstone transferred certain assets associated with the product to the Company. Legal fees of $90,000 associated with this buyout agreement have been capitalized as part of the purchase price. Additional estimated earnout costs due to Cornerstone of $589,000, recorded at fair value by the Company based upon a valuation provided by a third party valuation firm, were capitalized as part of the purchase price of this intangible asset. This earnout amount was revalued at December 31, 2014, resulting in a $167,000 increase in the estimated fair value of the earnout which is recorded in other income (expense), net in the Company's consolidated statements of operations. This earnout amount was revalued at December 31, 2015, resulting in a $542,000 decrease in the estimated fair value of the earnout which is recorded in other income (expense), net in the Company's consolidated statements of operations for the year ended December 31, 2015. This net decrease resulted primarily from new information regarding the projected impact of the DEA's reclassification of Tussionex from a Schedule III controlled substance to a Schedule II controlled substance. In addition, the Company paid $2.0 million to CPI to buy out their rights to future profits from the collaboration and entered into an agreement whereby CPI will continue to supply a component of the product. Legal fees of $43,000 associated with this buyout agreement have been capitalized as part of the purchase price of this intangible asset. These two intangible assets have an expected life of ten years and are being amortized on a straight-line basis beginning September 2014. Total amortization expense related to these intangible assets was $687,000 and $229,000 for the years ended December 31, 2015 and December 31, 2014, respectively. As a result of the discontinuation of nutraceuticals operations in 2013, the Company determined that the customer relationships and trade name that were related to that activity were fully impaired and the remaining carrying value of $544,000 was charged to expense within discontinued operations during the year ended December 31, 2013 (see Note 18). Aggregate amortization of intangible assets for each of the next five years and thereafter is as follows: Year ending December 31: December 31, 2015 (in thousands) 2016 $ 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Other assets

Other assets	12 Months Ended
	Dec. 31, 2015
Other assets
Other assets	Note 10. Other assets Other assets at the indicated dates consist of the following: December 31, 2015 2014 (in thousands) Patents $ $ Deposits ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents utilized in the manufacturing of the Company's generic Tussionex product which total $231,000 are being amortized over their expected useful life of 10 years. For the years ended December 31, 2015 and December 31, 2014, $23,000 and $31,000 of patent amortization expense was recorded, respectively.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes
Income Tax Disclosure	Note 11. Income taxes The Company applies FASB ASC topic 740, " Income Taxes" or ASC 740 which addresses the determination of whether tax benefits claimed, or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, our Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on derecognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company is generally subject to tax examination for a period of three years after tax returns are filed. Therefore, the statute of limitations remains open for tax years 2012 and forward. However, when a company has net operating loss carryovers, those tax years remain open until three years after the net operating losses are utilized. Therefore, the tax years remain open back to 2004. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities. The significant components of deferred income tax assets and liabilities consist of the following at December 31, 2015 and December 31, 2014: December 31, 2015 2014 (in thousands) Deferred Tax Assets: Net operating losses $ $ Accrued Expenses Inventory Share-based Compensation R&D tax credit Deferred lease liability Property and equipment Earnout Liability Deferred Gain on Sale Leaseback Litigation Costs Allowances ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets Deferred Tax Liabilities: Inventory Reserve ) — Capital lease liability ) ) Intangible assets ) ) State Deferreds ) — ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) Valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax asset (liability) $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2015, and 2014, the Company has federal net operating loss carry-forwards of $122,075,000 and $86,551,000 and research and development credits of $2,010,000 and $2,029,000, respectively, which begin to expire in 2024. The Company has state net operating loss carry-forwards of $278,000 and $0 for December 31, 2015 and December 31, 2014, respectively. Utilization of the net operating loss carry-forwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended and similar state provisions. The Company has performed an analysis to determine the impact of any ownership change(s) under Section 382 of the Internal Revenue Code. The amount of federal net operating loss that will expire unused due to the Section 382 limitation is $6,089,000. The amount of federal research and development credit that will expire unused is $350,000. The deferred tax assets for both carryforwards have been adjusted downward accordingly. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company's net operating loss carryforward and do not require recognition. As a result of these timing differences, at December 31, 2015 and December 31, 2014, the Company had gross unrecognized tax benefits related to uncertain tax positions of $4,355,000 and $835,000, respectively. The Company has no other tax positions taken or expected to be taken that would significantly increase or decrease unrecognized tax benefits within 12 months of the reporting date. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. A tabular rollforward of the Company's gross unrecognized tax benefits is below: December 31, 2015 2014 (in thousands) Beginning Balance $ $ — Increase/(Decrease) based on tax positions taken during a prior period — — Increase/(Decrease) based on tax positions taken during the current period ​ ​ ​ ​ ​ ​ ​ ​ Ending Balance $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The Company has recorded a valuation allowance of $38,331,000 at December 31, 2015 and $29,894,000 at December 31, 2014 to fully reserve its net deferred tax assets. The Company has assessed the likelihood that the deferred tax assets will be realized and determined that it is more likely than not that all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the uncertainty of realizing the deferred tax asset, the Company has placed a valuation allowance against the entire deferred tax asset. The change in the valuation allowance was an increase of $8,437,000 and $8,436,000 for the years ended December 31, 2015 and December 2014, respectively. A reconciliation of the Company's Federal statutory tax rate of 34% to the Company's effective income tax rate is as follows: December 31, 2015 2014 U.S. Statutory Tax Rate % % R&D Credit % % Change in Valuation Allowance )% )% Deferred Tax Adjustments )% % Provision to Return and Other Adjustments )% % ​ ​ ​ ​ ​ ​ ​ ​ Tax Expense/(Benefit) % % ​ ​ ​ ​ ​ ​ ​ ​

Long-term debt

Long-term debt	12 Months Ended
	Dec. 31, 2015
Long-term debt.
Long-term debt	Note 12. Long-term debt Long-term debt at the indicated dates consists of the following: December 31, 2015 2014 (in thousands) Senior debt, net of discount of $1,167 and $1,743 $ $ 10% subordinated note payable to a related party Capital leases, maturing through August 2017 ​ ​ ​ ​ ​ ​ ​ ​ Less current portion ) ) ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Credit Agreement: Previously, the Company had a credit agreement entered into on August 20, 2012 (the "Credit Agreement") with a financial institution. The Credit Agreement provided for a four-year $10.0 million term loan, with an annual interest rate of 9.5% payable monthly. In addition, a $250,000 fee payable at maturity was being amortized using the effective interest method. The proceeds from the initial $10.0 million draw on the LSA were used to repay the outstanding $10.0 million Credit Agreement balance and $697,000 of interest expense related to the Credit Agreement in March 2014. The early prepayment of the Credit Agreement resulted in a $445,000 loss (due to recording the $98,000 prepayment penalty and writing off the $154,000 unamortized exit fee and the $193,000 of unamortized loan cost) reflected in interest expense for the year ended December 31, 2014. Senior debt: On March 28, 2014, the Company entered into a Loan and Security Agreement ("LSA") with Hercules Technology Growth Capital, Inc., or Hercules, for a total commitment of $20.0 million, available in two tranches of $10.0 million. The first draw ("Tranche 1") was available immediately and the second draw was available upon the Company meeting certain regulatory or financial milestones. The Company received the initial $10.0 million tranche on March 28, 2014. This loan had an annual interest rate of 9.0%. The LSA also contained an end of term charge of 4.25% of the amount drawn, or a maximum of $850,000 total, also payable at the earliest to occur of (1) maturity, (2) the date we prepay our outstanding Secured Obligations, as defined therein, or (3) the date the Secured Obligations become due and payable. In connection with the LSA, the Company issued a Hercules Warrant to purchase 60,000 shares of Series C at the then current price of $5.00 per share, and the LSA provided for a Hercules Warrant for 60,000 shares of Series C at a price per share of $5.00 to be issued upon the drawdown of the second tranche. The proceeds from the initial $10.0 million draw were used to repay the outstanding $10.0 million Credit Agreement balance and $697,000 of interest expense related to the Credit Agreement in March 2014. The early prepayment of the Credit Agreement resulted in a $445,000 loss (due to recording the $98,000 prepayment penalty and writing off the $154,000 unamortized exit fee and the $193,000 of unamortized loan cost) reflected in interest expense for the year ended December 31, 2014. On September 25, 2014, the Company entered into an amendment ("LSA Amendment") to the LSA which was accounted for as a loan modification. The terms governing the $10.0 million previously drawn down under the LSA were not changed as a result of the LSA Amendment. The LSA Amendment modified, added or replaced the following key terms of the LSA: • Increased the maximum term loan amount from $20.0 million to $25.0 million, and modified the drawdown conditions for the remaining $15.0 million such that it is available in three $5.0 million tranches: $5.0 million being immediately available (which was drawn down immediately as "Tranche 2"), and two additional tranches being available upon meeting certain regulatory or financial milestones; • Adjusted the interest rate on $10.0 million of the remaining $15.0 million availability from 9.0% to 10.5%; the final $5.0 million tranche retains the original 9.0% interest rate; • Extended the end of term charge to the additional $5.0 million of availability such that the total end of term charge was increased from $850,000 to $1,062,500, and modified the end of term charge so that the full amount based on total commitment is payable regardless of whether additional tranches are actually drawn; and • Changed the interest and principal amortization dates if certain conditions are met to January 1, 2016 or May 1, 2016 if additional specified conditions are met. In addition, on September 25, 2014, the Company issued a Hercules Warrant to purchase 110,000 shares of its Series C at an exercise price of $5.00 per share, and cancelled the remaining commitment to issue any further warrants due upon future draws. The proceeds from the loan agreement draw-downs with the related stock purchase warrants were allocated to the two elements based on the fair value of the warrants at time of issuance and the remainder of the proceeds was allocated to the debt instrument portion of the transaction, resulting in a debt discount. The portion of the proceeds so allocated to the warrants is accounted for as warrant liability and periodically adjusted to fair value through the statement of operations. The related debt discount and end of term charges are amortized to interest expense over the contractual term of the debt using the effective interest method. The fair value of the 60,000 March 28, 2014 Hercules Warrants issued as part of the initial draw-down described above was $124,000 and the residual proceeds of $9,876,000 were allocated to the $10.0 million interest bearing note. The fair value of the 110,000 September 25, 2014 Hercules Warrants issued as part of the second draw-down described above was $248,000 and the residual proceeds of $4,752,000 were allocated to the $5.0 million interest bearing note. These warrants, known as the "Hercules Warrants", were recorded as a liability with a related debt discount to be amortized as interest over the term of the LSA. The Hercules Warrants became warrants for the purchase of 70,833 shares of common stock at a price of $12.00 per share upon the closing of the Company's IPO and were therefore reclassified from warrant liability to Additional Paid in Capital within Stockholders' Equity (Deficit) at July 22, 2015. On March 13, 2015, the Company received an advance from the lender for a $5.0 million tranche ("Tranche 3") under the LSA Amendment as a result of achievement of a certain regulatory milestone. In addition, on June 10, 2015, the Company received an advance from the lender for the final $5.0 million tranche ("Tranche 4") under the LSA, as amended, prior to meeting the milestones associated with the final tranche. The Company met the Tranche 4 Milestones stated in the LSA prior to July 31, 2015. Pursuant to the LSA as amended, each draw or tranche is to be repaid in monthly installments, comprised of interest-only monthly payments until May 2016, when installments of interest and principal calculated over a thirty-month amortization period commence. A balloon payment of the entire principal balance outstanding on October 1, 2017 and all accrued but unpaid interest thereunder is due and payable on October 1, 2017. The interest rate is 9% per annum for Tranche 1 and Tranche 4 and 10.5% per annum for Tranche 2 and Tranche 3. An end of term charge of $1.1 million is payable at the earliest to occur of (1) October 1, 2017, (2) the date the Company prepays its outstanding Secured Obligations, as defined therein, or (3) the date the Secured Obligations become due and payable. The LSA, as amended, also contains certain financial and nonfinancial covenants, including limitations on the Company's ability to transfer assets, engage in a change of control, merge or acquire with or into another entity, incur additional indebtedness, repurchase or redeem stock or other equity interest other than pursuant to employee stock repurchase plans or other similar agreements, make investments and engage in transactions with affiliates. Upon an event of default, Hercules may declare the unpaid principal amount of all outstanding loans and interest accrued under the LSA, as amended to be immediately due and payable, and exercise its security interests and other rights under the Credit Agreement. As of December 31, 2015 and December 31, 2014, the Company was in compliance with the covenants under the LSA, as amended. End of term charge amortization totaled $311,000 and $128,000 for the years ended December 31, 2015 and 2014, respectively. Debt discount amortization to interest expense for the senior debt totaled $265,000 and $140,000 for the years ended December 31, 2015 and December 31, 2014, respectively. As of July 22, 2015, the fair values of the Hercules Warrants were remeasured and a 2015 cumulative change in fair value of approximately $157,000 was recorded in other income (expense), net in the Company's consolidated statements of operations for the year ended December 31, 2015. 10% subordinated related party note: The Company has an amended and restated subordinated note (the "Note") in the aggregate principal amount of $5.9 million that was issued by the Company to Essex Capital Corporation ("Essex"). Interest accrues and adds to the principal balance until such time as the Company achieves positive EBITDA for three consecutive months. On July 19, 2014, the interest rate on the Note was reduced to 6% for the period from July 19, 2014 through June 28, 2015 pursuant to an amendment to the Note entered into as consideration for the $128,000 payment made by the Company to Essex as part of the Settlement and Release of Claims Agreement with Essex and a third party (see Note 16). The Company recorded this amendment as a loan modification. At December 31, 2015 and December 31, 2014, the aggregate principal amount of the Note was $5.9 million, and $1,059,000 and $511,000 in interest had been accrued through the years ended December 31, 2015 and 2014, respectively. Capital lease obligations to related party: As described in Notes 8 and 19, during the years ended December 31, 2014 and 2013, the Company entered into agreements with a related party for the sale-leaseback of existing and newly acquired assets with a total capitalized cost of $795,000 and $5.5 million, respectively, which are classified as capital leases. The approximate imputed interest rate on these leases is 14.5% and interest expense on these leases was $467,000, $662,000 and $474,000 for the years ended December 31, 2015, 2014 and 2013, respectively. Future minimum capital lease payments are as follows: Year ending: December 31, (in thousands) 2016 $ 2017 ​ ​ ​ ​ ​ Total minimum lease payments Less amount representing interest ​ ​ ​ ​ ​ Future minimum lease payments $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future principal payments of long-term debt, including capital leases, are as follows: Year ending: December 31, 2015 (in thousands) 2016 $ 2017 ​ ​ ​ ​ ​ Future principal payments $ ​ ​ ​ ​ ​ Less unamortized debt discount ) Less current portion of long-term debt ) ​ ​ ​ ​ ​ Total long-term debt $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Common stock and redeemable con

Common stock and redeemable convertible preferred stock	12 Months Ended
	Dec. 31, 2015
Common stock and redeemable convertible preferred stock
Common stock and redeemable convertible preferred stock	Note 13. Common stock and redeemable convertible preferred stock The following table summarizes the authorized, issued and outstanding shares of the Company by class of stock as of December 31, 2015 and 2014. All shares have a par value of $0.001: December 31, 2015 December 31, 2014 Authorized Shares Issued and Outstanding Shares Authorized Shares Issued and Outstanding Shares Common Stock Preferred Stock — — — Series A Preferred Stock — — Series B Preferred Stock — — Series B-1 Preferred Stock — — Series C Preferred Stock — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Shares Issued ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Treasury Stock ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Outstanding Shares ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Authorized Shares ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prior to the Company's IPO, the Company had classified its classes of redeemable convertible preferred stock as mezzanine equity based upon the terms and conditions which contain various redemption and conversion features. The Company evaluated its redeemable convertible preferred stock for potential embedded derivatives. In doing so, the Company first concluded that the nature of the host contract was more equity than debt like. The embedded conversion features were determined not to be derivatives as net settlement did not exist. Additionally, the conversion features are clearly and closely related to an equity host contract. Consideration was also given to whether a beneficial conversion feature should be recognized in additional paid in capital for the intrinsic value of the conversion feature at the issuance date. None was recognized given that the effective conversion price exceeded the value of the common stock on that date. The redemption feature was deemed not to be a derivative since settlement would be gross. In connection with the sale of shares of the Company's Series B-1 Redeemable Convertible Preferred Stock ("Series B-1"), the Series B-1 investors also received warrants to purchase 389,474 shares of common stock at an exercise price of $.0024 per share ("Series B-1 warrants"). In 2013, 520 shares of common stock were issued as a result of the exercise of certain of the Series B-1 warrants. There were no exercises of Series B-1 warrants in 2014. During the year ended December 31, 2015, the Company issued a total of 286,968 shares of its common stock upon the exercise of Series B-1 warrants held by several investors at an exercise price of $0.0024 per share. As of December 31, 2015, Series B-1 warrants to purchase 50,158 shares of common stock remained outstanding, and expire in 2016. In February and March 2014, the Company closed on additional Series C financings totaling 1,986,586 shares, raising $9.9 million. On December 31, 2014, the Company closed on an additional Series C financing which included the issuance of a warrant to purchase one additional share of Series C at a purchase price of $5.00 per share for every two purchased shares of Series C provided the investor purchased its pro-rata share of the Series C. In the event that the Company's Series C is converted into common stock or another class of the Company's stock (called "Conversion Stock") during the warrant exercise period, then the warrants will become exercisable for the Conversion Stock and the exercise price of those warrants shall be ratably adjusted. The December 2014 Series C financing resulted in the issuance of 1,499,935 shares and 749,967 warrants (see warrant liability section below) and raised $7.5 million. Between December 2014 and February 25, 2015, the Company closed on additional Series C financings totaling 4,124,871 shares and 1,947,185 warrants, raising a total of $20.6 million, of which 2,624,936 shares and 1,197,218 warrants were issued and $13.1 million was received after December 31, 2014. From June 30, 2015 through July 27, 2015, the Company issued a total of 1,000,000 shares of its Series C to several investors upon the exercise of warrants held by those investors at an exercise price of $5.00 per share, for an aggregate exercise price of $5 million. Reverse Stock Split On July 10, 2015, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a 1-for-2.4 reverse stock split of the Company's issued and outstanding shares of common stock as approved by the board of directors on July 9, 2015. All issued and outstanding common stock and per share amounts contained in the Company's financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. Authorized Shares In connection with the closing of the Company's IPO on July 28, 2015, the Company amended and restated its certificate of incorporation to authorize 5,000,000 shares of preferred stock, par value $0.001 per share, and 100,000,000 shares of common stock, par value $0.001 per share. Public Offerings and Related Transactions On July 28, 2015, the Company closed its IPO whereby the Company sold 5,520,000 shares of common stock, at a public offering price of $15.00 per share, which includes 720,000 shares of common stock resulting from the underwriters' exercise of their over-allotment option at the IPO price on July 23, 2015. Proceeds from the Company's IPO, net of underwriting discounts and commissions and other offering costs, were $75.0 million. Upon the closing of the Company's IPO, all of the Company's Preferred Shares converted into shares of the Company's Common Stock, all such Preferred Shares were retired and cancelled and shall not be reissued as shares of such series, and all rights and preferences of those Preferred Shares were cancelled including the right to receive undeclared accumulated dividends. Each of the following occurred in connection with the closing of the Company's IPO on July 28, 2015: • the conversion of all outstanding shares of convertible preferred stock into 9,217,983 shares of the Company's common stock; • the conversion of the Hercules Warrants to purchase 170,000 shares of Series C into warrants to purchase 70,833 shares of the Company's common stock and the resultant reclassification of the warrant liability to Additional Paid in Capital within Stockholders' Equity (Deficit); and • the net exercise of outstanding Series C warrants issued in conjunction with the Series C financing to purchase 947,185 shares of Series C for 78,926 shares of the Company's common stock. In accordance with the conversion provision of the Company's Third Amended and Restated Certificate of Incorporation, as amended, which was triggered upon the Company's IPO, all rights with respect to the Preferred Shares of the Company were terminated, including redemption rights. Prior to the closing of the Company's IPO, the rights and preferences of the preferred stock were as follows: Dividends: Dividends could not be paid on the common stock unless equivalent or larger dividends had been paid to holders of the Series C, Series B-1, Series B and Series A Redeemable Convertible Preferred Stock ("Series A") on an as-if converted basis and other financial tests, as defined, had been met. From and after the date of the issuance of the Series B-1 until the retirement and cancellation of Series B-1 in conjunction with the Company's IPO, dividends at the rate per annum of 8% of the Series B-1 original issuance price of $5.00 were accrued on such shares of Series B-1. Dividends accrued from day to day, whether or not declared, and were cumulative. The accruing dividends were to be payable in additional shares of Series B-1, valued at the Series B-1 original issuance price, unless the board of directors of the Company elected to pay all or any portion of the accruing dividends in cash. In accordance with the conversion provision of the Company's Third Amended and Restated Certificate of Incorporation, as amended, which was triggered upon the Company's IPO, all rights with respect to the Preferred Shares of the Company were terminated, including the right to receive undeclared dividends. The Series B-1 cumulative dividends were never declared by the Company's board of directors. Voting: The holders of Series C, Series B-1, Series B and Series A were entitled to cast the number of votes equal to the number of whole shares of common stock into which such shares of preferred stock held by such holder were convertible. Liquidation: In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Series C then outstanding were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment could be made to the holders of Series B-1, Series B, Series A or common stock, an amount per share equal to their original issuance price of $5.00 per share, plus any declared but unpaid dividends. The holders of Series B-1 and Series B then outstanding were then entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment could be made to the holders of Series A or common stock, an amount per share equal to their original issuance price of $5.00 per share, plus any declared but unpaid dividends, plus any accrued dividends for the Series B-1. In addition to the payments above, the holders of Series B-1 then outstanding were then entitled to be paid an additional amount out of the assets of the Company available for distribution to its stockholders, before any payment could be made to the holders of Series A or common stock, an amount per share equal to their original issuance price of $5.00 per share. The holders of Series A then outstanding were then entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment could be made to the holders of common stock, an amount per share equal to their original issuance price of $5.00 per share, plus any declared but unpaid dividends. If there were any residual amounts available to be paid out of the assets of the Company, such amounts were to be distributed ratably to the holders of Series B, Series B-1 and Series C shares and the holders of the common stock. Although holders of Series A received no ratable residual distribution, such holders could exercise their option and convert to common shares, thereby also receiving a ratable distribution of any such residual amounts available to be paid out. Redemption: Prior to the retirement and cancellation of the Company's Preferred Shares as a result of the IPO, the holders of a majority of the outstanding shares of Series C, Series B-1 and Series B, voting together as a single class, could require the Company to redeem the Series C, Series B-1 and Series B at their original purchase price of $5.00 per share in three annual installments by giving a sixty-day notice at any time on or after March 31, 2017. On March 25, 2014, the Company amended the initial redemption date, extending it to November 1, 2017. On each redemption date, the Company was to redeem, on a pro rata basis in accordance with the number of shares of Series C, Series B-1 and Series B owned by each holder, that number of outstanding shares of Series C, Series B-1 and Series B. If the Company did not have sufficient funds legally available to redeem on any redemption date, the Company was to redeem a pro rata portion of each holder's Series C, Series B-1 and Series B out of funds legally available. The Series C, Series B-1 and Series B were to be redeemable on November 1, 2017, their carrying value was being accreted to the minimum redemption value of $5.00 per share or $43,768,000, $27,309,000 and $15,565,000, respectively, over the period from issuance through November 1, 2017 using the effective interest method for issuances through December 31, 2014. Due to the additional issuances of Series C prior to the IPO, the Series C was accreted to the increased minimum redemption value of $5.00 per share, or $57,642,000, over the period from issuance through the IPO effective date using the effective interest method. The amount of accretion recorded in 2015, 2014 and 2013 for Series C amounted to $607,000, $87,000 and $78,000, respectively. The amount of accretion recorded in 2015, 2014 and 2013 for Series B-1 was $370,000, $679,000 and $756,000, respectively. The amount of accretion recorded in 2015, 2014 and 2013 for Series B amounted to $192,000, $352,000 and $394,000, respectively. In accordance with the conversion provision of the Company's Third Amended and Restated Certificate of Incorporation, as amended, which was triggered upon the Company's IPO, all rights with respect to the Preferred Shares of the Company were terminated, including redemption rights. Warrant liability: In connection with the December 2014 $7.5 million additional Series C financing (see above) the Company issued warrants to purchase an aggregate 749,967 shares of the Series C. The proceeds from the December 2014 additional Series C financing with stock purchase warrants were allocated to the two elements based on the fair value of the Series C warrants at time of issuance. The remainder of the proceeds was allocated to the redeemable convertible preferred instrument portion of the transaction, resulting in a discount. The portion of the proceeds so allocated to the warrants is accounted for as a warrant liability and periodically adjusted to fair value through the statement of operations. The related preferred stock discount is amortized as preferred stock accretion to redemption value over the remaining term until the redemption date using the effective interest method. The fair value of the 749,967 Series C Warrants was $1,335,000, with the residual $6,108,000, net of legal fees of $57,000, allocated to the 1,499,935 shares of Series C as of Deceember 31, 2014. The proceeds from the 2015 additional Series C financing with stock purchase warrants were allocated to the two elements based on the fair value of the Series C warrants at time of issuance. The remainder of the proceeds was allocated to the redeemable convertible preferred instrument portion of the transaction, resulting in a discount. The portion of the proceeds so allocated to the warrants is accounted for as a warrant liability and periodically adjusted to fair value through the statement of operations. The related preferred stock discount is amortized as preferred stock accretion to redemption value over the remaining term until the redemption date using the effective interest method. The fair value of the 1,197,218 Series C warrants was $2,131,000, with the residual $10,916,000, net of legal fees of $78,000, allocated to the 2,624,936 shares of Series C. On the IPO effective date of July 22, 2015, the Series C warrant fair values were remeasured for a final time and an increase in fair value of approximately $1,698,000 has been recorded in other income (expense), net in the Company's consolidated statements of operations for year ended December 31, 2015. Upon the closing of the Company's IPO, all of the shares of the Company's redeemable convertible preferred stock ("Preferred Shares") were retired and cancelled and shall not be reissued as shares of such series, and all rights and preferences of those Preferred Shares were cancelled including the right to receive undeclared accumulated dividends. On the IPO closing date, all outstanding shares of redeemable preferred stock converted into 9,217,983 shares of common stock and all remaining outstanding Series C warrants issued in conjunction with purchases of Series C were net exercised at the IPO price for 78,926 shares of common stock.

Stock options, restricted stock

Stock options, restricted stock and performance stock options	12 Months Ended
	Dec. 31, 2015
Stock options, restricted stock and performance stock options
Stock options, restricted stock and performance stock options	Note 14. Stock options, restricted stock and performance stock options In July 2015, the Company adopted the Neos Therapeutics, Inc. 2015 Stock Option and Incentive Plan ("2015 Plan") which became effective immediately prior to the closing of the IPO and initially had 767,330 shares of common stock reserved for issuance. On January 1, 2016 and each January 1 thereafter, the number of shares of common stock reserved and available for issuance under the 2015 Plan shall be cumulatively increased by five percent of the number of shares of stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares determined by the administrator of the 2015 Plan (the "Evergreen Provisions"). The 2015 Plan superseded the Neos Therapeutics, Inc. 2009 Equity Plan ("2009 Plan"), originally adopted in November 2009 and which had 1,375,037 shares for reserved and available for issuance. Effective upon closing of the IPO, the board of directors determined not to grant any further awards under the 2009 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise) under the 2009 Plan will be added to the shares of common stock available under the 2015 Plan. This number is subject to adjustment in the event of a stock split, stock dividend or other change in the Company's capitalization. The 2015 Plan is administered by the Company's compensation committee. The Company's compensation committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants and to determine the specific terms and conditions of each award, subject to the provisions of the 2015 Plan. The Company's compensation committee may delegate authority to grant certain awards to the Company's chief executive officer. The exercise price per share for the stock covered by a stock option granted shall be determined by the administrator at the time of grant but shall not be less than 100 percent of the fair market value on the date of grant. Unexercised options under the 2015 Plan expire after the earlier of 10 years or termination of employment, except in the case of any unexercised vested options, which generally expire 90 days after termination of employment. The 2009 Plan allowed the Company to grant options to purchase shares of the Company's common stock. Options were granted to officers, employees, nonemployee directors and consultants, and independent contractors of the Company. The Company also granted performance based awards to selected management. The performance options vest over a three-year period based on achieving certain operational milestones. Unexercised options under the 2009 Plan expire after the earlier of 10 years or termination of employment, except in the case of any unexercised vested options, which generally expire 90 days after termination of employment. All terminated options are available for reissuance under the 2015 Plan. Since the inception of the 2015 Plan through December 31, 2015, 1,389 shares related to forfeited 2009 Plan options and 9,197 shares of surrendered restricted stock were transferred into the shares available under the 2015 Plan. As of December 31, 2015, 166,040 shares of common stock remain available for grant under the 2015 Plan. The Company estimates the fair value of all stock option awards on the grant date by applying the Black-Scholes option pricing valuation model. The application of this valuation model involves assumptions that are highly subjective, judgmental and sensitive in the determination of compensation cost. Prior to the IPO, given the absence of an active market for the Company's common stock prior to its IPO, the Company's board of directors was required to estimate the fair value of its common stock at the time of each option grant primarily based upon valuations performed by a third party valuation firm. The weighted-average key assumptions used in determining the fair value of options granted during the periods indicated are as follows: Year Ended December 31, 2015 2014 2013 Estimated dividend yield % % % Expected stock price volatility % % % Weighted-average risk-free interest rate % % % Expected life of option in years Weighted-average option fair value at grant $ $ $ Total compensation cost that has been charged to general and administrative expense related to stock options was $1,087,000, $120,000 and $52,000 for the years ended December 31, 2015, 2014 and 2013, respectively. At December 31, 2015, there was $7.5 million of unrecognized compensation cost, adjusted for estimated forfeitures, related to unamortized stock options compensation which is expected to be recognized over 3.1 years. For the year ended December 31, 2015, the Company issued 38,307 shares of the Company's common stock upon the exercise of outstanding stock options and received proceeds of $74,000 and realized no tax benefit from the exercised stock options. For the year ended December 31, 2014, the Company issued 13,408 shares of the Company's common stock upon the exercise of outstanding stock options and received proceeds of $4,000 and realized no tax benefit from the exercised of stock options A summary of outstanding and exercisable options as of December 31, 2015 and 2014, and changes during the periods then ended is presented below: Number of Options Weighted- Average Exercise Price Intrinsic Value (in thousands) Outstanding at January 1, 2013 $ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2013 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2013 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2014 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2014 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2015 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2015 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The weighted-average remaining contractual life of options outstanding and exercisable on December 31, 2015 was 8.9 and 7.3 years, respectively. The option exercise price for all options granted in the year ended December 31, 2015 ranged from $9.32 to $25.50 per share. Restricted stock: Under the 2009 Plan, the Company grants restricted stock awards to members of its management and selected members of the board of directors. Restricted stock awards are recorded as deferred compensation and amortized into compensation expense, on a straight-line basis over a defined vesting period ranging from 1 to 48 months. For the year ended December 31, 2013, the Company issued 149,244 shares of restricted stock at a grant date fair value of $2.55 per share. Of these shares, 7,195 vested immediately and the remaining 142,049 of these shares vest over 48 months in four equal tranches on the anniversary of the issue date. The Company did not issue any shares of restricted stock for the years ended December 31, 2015 or December 31, 2014. During the years ended December 31, 2015, 2014 and 2013, $94,000, $90,000 and $47,000, respectively, of restricted stock compensation cost has been charged to general and administrative expenses. At December 31, 2015, there was $162,000 of unrecognized compensation cost related to restricted stock which will be recognized over 1.8 years. In 2014, the Company settled certain vested restricted stock awards which were settled having a value of $266,000 in cash, and the Company realized a tax benefit of $90,000. On October 16, 2015, the Company settled certain vested restricted stock awards which were settled having a value of $658,000 in cash, and the company realized a tax benefit of $224,000. On October 16, 2015, 9,197 shares of restricted stock were surrendered by the holder to the Company to cover taxes associated with vesting of restricted stock. The fair value of such shares was determined to be $18.54 per share, the closing price of the Company's stock on such date. The Company had 71,025 and 106,537shares of unvested restricted stock with a weighted average fair value of $2.55 as of December 31, 2015 and 2014, respectively. A summary of the status of the Company's nonvested restricted stock as of December 31, 2015 and December 31, 2014, and changes during the periods ended December 31, 2015 and December 31, 2014, is presented below: Number of Shares Weighted- Average Grant Date Fair Value Nonvested at January 1, 2013 $ Granted Vested ) Forfeited ) ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at January 1, 2014 $ Granted — — Vested ) Forfeited — — ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted — — Vested ) Forfeited — — ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at December 30, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Treasury stock

Treasury stock	12 Months Ended
	Dec. 31, 2015
Treasury stock
Treasury stock	Note 15. Treasury stock The Company has the authority to repurchase common stock from former employees, officers, directors or other persons who performed services for the Company at the lower of the original purchase price or the then-current fair market value. In 2013, the Company repurchased 55,905 shares of common stock at the original purchase price of $0.002. On February 19, 2015, the Company's board of directors approved the cancellation of the Company's 55,905 shares of treasury stock which had been repurchased at the original purchase price of $0.002 in 2013. On October 16, 2015, 9,197 shares of restricted stock were surrendered by the holder to the Company to cover taxes associated with vesting of restricted stock and such shares were added back into the treasury stock of the Company.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and contingencies
Commitments and contingencies	Note 16. Commitments and contingencies Defined contribution plans: The Company has a 401(k) investment plan covering substantially all employees. Employees are allowed to contribute annually up to 50% of their compensation, to a maximum of $17,500. Employees who have attained age 50 before the end of the plan year are eligible to make catch up contributions of up to $5,500. Through December 31, 2014, the Company was required to make a matching contribution to the 401(k) plan of 50%, to a limit of 6%, of the participant's annual compensation, which was paid in the first quarter of 2015. Effective January 1, 2015, the Company amended its qualified 401(k) savings plan to provide a Company matching contribution on the first 3% of an employee's salary and to match 1/2% of the next 2% of an employee's salary, for a total possible match of 4%, subject to statutory limitations as prescribed by law. For the years ended December 31, 2015, 2014 and 2013, the Company recorded $186,000, $82,000 and $91,000, respectively, of expense for 401(k) contributions. Operating leases: The Company leases its Grand Prairie office space and manufacturing facility under an operating lease which expires in 2024. In addition, the Company executed in December 2015, a 60-month lease for office space in Blue Bell, Pennsylvania for its commercial operations which is planned to commence on May 1, 2016. Total future minimum lease payments under these operating leases with noncancelable terms are as follows: Year ending December 31, (in thousands) 2016 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ Future minimum lease payments $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The Company accounts for rent expense on long-term operating leases on a straight-line basis over the life of the lease resulting in a deferred rent balance of $1,166,000 and $1,189,000 at December 31, 2015 and December 31, 2014, respectively. The Company is also liable for a share of operating expenses for both premises as defined in the lease agreements. The Company's share of these operating expenses for the Grand Prairie facility was $237,000, $251,000 and $208,000 for the years ended December 31, 2015, 2014 and 2013, respectively. Rent expense for these leases, excluding the share of operating expenses, was $884,000, $896,000 and $879,000 for the years ended December 31, 2015, 2014 and 2013, respectively. The Company did not have a share of operating expenses for the Pennsylvania lease in 2015. Cash incentive bonus plan: In July 2015, the Company adopted the Senior Executive Cash Incentive Bonus Plan ("Bonus Plan"). The Bonus Plan provides for cash payments based upon the attainment of performance targets established by the Company's compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to the Company, or corporate performance goals, as well as individual targets. The Company has recorded $552,000 of compensation expense for the year ended December 31, 2015 under the Bonus Plan.

License agreements

License agreements	12 Months Ended
	Dec. 31, 2015
License agreements
License agreements	Note 17. License agreements On July 23, 2014, the Company entered into a Settlement Agreement and an associated License Agreement with Shire LLC for a non-exclusive license to certain patents for certain activities with respect to the Company's new drug application No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet ("Neos NDA"). Under the terms of the agreement, the Company is required to pay a lump sum, non-refundable license fee of an amount less than $1.0 million no later than 30 days after receiving regulatory approval by the FDA of the Neos NDA (see Note 21 for subsequent payment). The Company will also pay a single digit royalty on net sales of the subject product during the life of the patents. The license fee will be capitalized and amortized over the life of the patents. The royalties will be recorded as cost of goods sold in the same period as the net sales upon which they are calculated.

Discontinued operations

Discontinued operations	12 Months Ended
	Dec. 31, 2015
Discontinued operations
Discontinued operations	Note 18. Discontinued operations In March 2013, the Company discontinued the manufacturing of nutraceuticals for third parties in order to concentrate on the manufacture of extended-release pharmaceutical products. In accordance with Topic ASC, 360-10, the results of operations for the contract manufacturing of nutraceuticals has been excluded from continuing operations and reported as discontinued operations for the prior period. The components of discontinued operations which relate to contract manufacturing of nutraceuticals are as follows: 2013 (in thousands) Revenue $ Direct costs Impairment of intangible assets ​ ​ ​ ​ ​ Net loss from discontinued operations $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2015
Related party transactions
Related party transactions	Note 19. Related party transactions At December 31, 2015 and December 31, 2014, the Company was obligated under a $5,935,000 long-term subordinated note ("Note") that was issued by the Company to Essex. See Note 12 for further details. On July 21, 2014, the Company, Essex and a third party entered into a Settlement Agreement and Release of Claims Agreement resolving certain issues and disputes whereby Essex paid $256,000 to the third party, the Company paid Essex $128,000 and Essex agreed to reduce the interest rate on the Note from 10% to 6% for the July 19, 2014 through July 31, 2015 period. The third party released both Essex and the Company from any and all claims. As described in Note 12, in 2012, the Company negotiated financing arrangements with a related party that provided for the sale-leaseback of up to $6.5 million of the Company's property and equipment. In 2013, the Company executed four transactions totaling $5.5 million and in March 2014, the Company completed the final tranche of the sale-leaseback arrangement, raising an additional $795,000. During 2014 and 2013 the Company contracted for approximately $112,000 and $499,000, respectively, in consulting and testing services with a company affiliated with the Company's Chairman of the board of directors. As the Company's Chairman is no longer affiliated with this consulting and testing services company, there are no such related party transactions in 2015. The cost of the acquired services was negotiated at arm's length and priced at commercially available rates

Selected Quarterly Financial Da

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2015
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data	Note 20. Selected Quarterly Financial Data (Unaudited) The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Operating results for these periods are not necessarily indicative of the operating results for a full year. Historical results are not necessarily indicative of results to be expected in future periods. Selected quarterly financial data for years ended December 31, 2015 and 2014, are as follows (in thousands, except share and per share amounts): Quarter Ended March 31, 2014 June 30, 2014 September 30, 2014 December 31, 2014 Net Sales $ $ $ ) $ Gross loss ) ) ) ) Net Loss $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock Accretion to Redemption Value ) ) ) ) Preferred Stock Dividends ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stock $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute net loss per share, basic and diluted(2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share of common stock, basic and diluted(1): $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 Net Sales $ $ $ $ Gross loss ) ) ) ) Net Loss $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock Accretion to Redemption Value ) ) ) — Preferred Stock Dividends ) ) ) — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stock $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute net loss per share, basic and diluted(2)(3) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share of common stock, basic and diluted(1): $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year. (2) In connection with the IPO, the Company's Board of Directors approved a 1-for-2.4 reverse stock split of the Company's common stock which also resulted in a proportional adjustment to the conversion ratios of the preferred stock and the preferred stock warrants. All references to common stock and per share amounts in these condensed financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split. (3) Between June 30, 2015 and July 27, 2015, the Company issued a total of 1,000,000 shares of its Series C redeemable convertible preferred stock to several existing investors upon the exercise of warrants to purchase Series C preferred stock held by those investors at an exercise price of $5.00 per share, for an aggregate exercise price of $5.0 million. On the IPO closing date, all outstanding shares of redeemable preferred stock converted into 9,217,983 shares of common stock and all remaining outstanding Series C warrants issued in conjunction with purchases of Series C preferred stock were net exercised at the IPO price for 78,926 shares of common stock. Upon the closing of the Company's IPO, all of the shares of the Company's redeemable convertible preferred stock were retired and cancelled and shall not be reissued as shares of such series, and all rights and preferences of those Preferred Shares were cancelled including the right to receive undeclared accumulated dividends. On July 28, 2015, the Company closed its initial public offering whereby the Company sold 5,520,000 shares of common stock, at a public offering price of $15.00 per share, which includes 720,000 shares of common stock resulting from the underwriters' exercise of their over-allotment option at the IPO price on July 23, 2015. These transactions produced a significant increase in the number of shares outstanding which will impact the year-over-year comparability of the Company's loss per share calculations.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2015
Subsequent events
Subsequent events	Note 21. Subsequent events Events occurring after December 31, 2015 and through the date on which these consolidated financial statements were issued were evaluated for any subsequent events requiring recognition or disclosure and have been incorporated into these consolidated financial statements. Between January 1 and March 17, 2016, the Company issued 19,090 shares of its common stock to several investors upon the exercise of Series B-1 warrants held by those investors at an exercise price of $0.0024 per share (see Note 13). On January 1, 2016, in accordance with the Evergreen Provisions of the 2015 Plan, the Company added 800,797 shares to the option pool, increasing the total number of shares reserved and available for issuance under the 2015 Plan to 966,837 shares. On January 27, 2016, the Company received approval from the FDA for its Adzenys XR-ODT product and paid the lump sum, non-refundable license fee of an amount less than $1.0 million on February 26, 2016 (see Note 17).

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Schedule II - Valuation and Qualifying Accounts
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (in thousands) Balance at beginning of period Additons charged to costs and expenses Other additions Deductions Balance at end of period For the year ended December 31, 2015 Allowance for chargebacks (1) $ $ $ — $ ) $ Allowance for cash discounts (1) — ) Reserve for wholesaler fees (2) — ) Reserve for returns (2) — ) Government rebates (2) — ) For the year ended December 31, 2014 Allowance for chargebacks (1) — — ) Allowance for cash discounts (1) — — ) Reserve for wholesaler fees (2) — — ) Reserve for returns (2) — — — Government rebates (2) — — — (1) Shown as a reduction of accounts receivable and gross sales. (2) Shown as accrued expenses and a reduction of gross sales.

Summary of significant accoun30

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2015
Summary of significant accounting policies
Principles of consolidation	Principles of consolidation: At December 31, 2015, the consolidated financial statements include the accounts of the Company and its four wholly-owned subsidiaries. At December 31, 2014, Neos Therapeutics, Inc. owned, directly or indirectly, 100% of two of its subsidiaries and 99.9% of the third subsidiary, Neostx, Inc. ("NTX"). The remaining 0.1% ownership of NTX was held by a third party and all such remaining capital stock was acquired by the Company on June 29, 2015, and NTX was merged with and into the Company. The amounts attributable to the noncontrolling interest were not material to the consolidated financial statements. On September 16, 2015, the Company established two new wholly-owned subsidiaries, Neos Therapeutics Brands, LLC and Neos Therapeutics Commercial, LLC. All significant intercompany transactions have been eliminated.
Cash equivalents	Cash equivalents: The Company invests its available cash balances in bank deposits and money market funds. The Company considers highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company's primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity.
Short-term investments	Short-term investments: Short-term investments consist of U.S. Treasury Bills that have original maturities greater than three months but less than or equal to one year and are classified as available-for-sale securities. These investments are recorded at fair value. Realized gains and losses are reported in the consolidated statements of operations. Unrealized gains and losses are immaterial.
Allowance for doubtful accounts	Allowance for doubtful accounts: The allowance for doubtful accounts is maintained at a level considered adequate to provide for losses that can be reasonably anticipated. Management determines the adequacy of the allowance based on reviews of individual accounts, historical losses, existing economic conditions and estimates based on management's judgments in specific matters. Accounts are written off as they are deemed uncollectible based on periodic review of the accounts. There is no allowance for doubtful accounts at December 31, 2015 or December 31, 2014, as management believes that all receivables are fully collectible.
Fair value of financial instruments	Fair value of financial instruments: The carrying value of the Company's financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, other current assets, accounts payable, accrued expenses, and debt, approximates fair value due to the short-term nature of the instruments and/or the current interest rates payable in relation to current market conditions. The fair value of the Company's warrants and earnout liabilities is disclosed in Note 5.
Inventories	Inventories: Inventories, comprised of raw materials, labor, and manufacturing overhead, as well as finished goods inventory, are stated at the lower of cost (actual, which approximates first-in, first-out) or market, net of an allowance for obsolete inventory.
Property and equipment	Property and equipment: Property and equipment is recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the respective lease term or the estimated useful lives of the assets.
Intangible assets	Intangible assets: Intangible assets subject to amortization, which principally include proprietary modified-release drug delivery technology and the costs to acquire the rights to Tussionex ANDA, are recorded at cost and amortized over the estimated lives of the assets ranging from 10 to 20 years.
Impairment of long-lived assets	Impairment of long-lived assets: Long-lived assets such as property and equipment and intangibles subject to amortization are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable. Such assets are also evaluated for impairment in light of the Company's continuing losses. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment charges were recorded for the years ended December 31, 2015 or December 31, 2014. Impairment charges of intangible assets related to the discontinued nutraceutical manufacturing operations of $544,000 were recognized in the year ended December 31, 2013.
Patent costs	Patent costs: The Company estimates that the patents it has filed have a future beneficial value. Therefore, costs associated with filing for its patents are capitalized. Once the patent is approved and commercial revenue realized, the costs associated with the patent are amortized over the useful life of the patent. If the patent is not approved, the costs will be expensed.
Revenue recognition	Revenue recognition: Revenue is generated from product sales, recorded on a net sales basis, and historically, manufacturing, development and profit sharing from a development and manufacturing agreement. Product revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed and determinable; and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid for the product, or the buyer is obligated to pay for the product and the obligation is not contingent on resale of the product, (3) the buyer's obligation to pay would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. The Company sells its generic Tussionex to a limited number of pharmaceutical wholesalers. Pharmaceutical wholesalers buy drug products directly from manufacturers. Title to the product passes upon delivery to the wholesalers, when the risks and rewards of ownership are assumed by the wholesaler (freight on board destination). These wholesalers then resell the product to retail customers such as food, drug and mass merchandisers. The Company's manufacturing, profit sharing and development revenue ended in 2014 as the Company has terminated the Company's development and manufacturing agreement. As a result of the Company's acquisition of the rights to commercialize and derive future profits from the Tussionex ANDA, the Company will utilize its manufacturing capability to derive revenue directly from sales made by the Company, rather than through the Company's commercial partner.
Net product sales	Net product sales Net product sales for the Company's generic Tussionex product represent total gross product sales less gross to net sales adjustments. Gross to net sales adjustments include wholesaler fees and estimated allowances for product returns, government rebates, chargebacks and prompt-payment discounts to be incurred on the selling price of the respective product sales. Wholesale distribution fees are incurred on the management of these products by wholesalers and are recorded within net product sales based on definitive contractual agreements. The Company estimates gross to net sales adjustments for allowances for product returns, government rebates and chargebacks based upon analysis of third-party information, including information obtained from the Company's third party logistics provider, or 3PL, with respect to their inventory levels and sell-through to the wholesalers' customers, data available from third parties regarding prescriptions written for the Company's products, as well as actual experience as reported by the Company's customers and previous commercialization partners. Due to estimates and assumptions inherent in determining the amount of returns, rebates and chargebacks, the actual amount of returns and claims for rebates and chargebacks may be different from the estimates, at which time reserves would be adjusted accordingly. Allowances and accruals are recorded in the same period that the related revenue is recognized.
Product returns	Product returns Wholesalers' contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. Generic Tussionex product returns are estimated based upon data available from sales of the Company's product by its previous commercialization partner and from actual experience as reported by retailers. Historical trend of returns will be continually monitored and may result in future adjustments to such estimates. On August 26, 2014, the U.S. Drug Enforcement Agency reclassified the Company's generic Tussionex from a Schedule III controlled substance to a Schedule II controlled substance which had the effect of requiring unsold product at the wholesalers and the 3PL to either be relabeled or returned. This new ruling was effective October 6, 2014. As such, the Company established reserves for the estimated returns of such product outstanding at the wholesalers as of October 6, 2014. The Company had no inventory labeled as Schedule III at the 3PL as of the effective date.
Medicaid rebates	Medicaid rebates The Company's products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Estimated rebates payable under governmental programs, including Medicaid, are recorded as a reduction of revenue at the time revenues are recorded. For generic Tussionex, calculations related to these rebate accruals are estimated based on sales of the Company's product by its previous commercialization partner. Historical trend of Medicaid rebates will be continually monitored and may result in future adjustments to such estimates.
Wholesaler Chargebacks	Wholesaler Chargebacks The Company's products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company. Chargebacks are accounted for by establishing an accrual in an amount equal to the Company's estimate of chargeback claims at the time of product sale based on information provided by the distributor. Due to estimates and assumptions inherent in determining the amount of chargebacks, the actual amount of claims for chargebacks may be different from estimates, which may result in adjustments to such reserves.
Manufacturing	Manufacturing Manufacturing revenue is derived from product manufactured by the Company and sold by the Company's commercial partner under a development and manufacturing agreement. Manufacturing revenue is derived from a contractual supply price paid to the Company by the Company's commercial partners.
Profit sharing	Profit sharing Profit sharing revenue is recorded as the product is sold by the Company's commercial partner. The profit share is the Company's share of the net profits after taking into account net revenue, which is gross product sales by the Company's commercial partner, net of discounts, returns and allowances incurred by the Company's commercial partner, less collaboration expenses.
Development revenue	Development revenue Development revenue from the development and manufacturing agreement has been recognized as the related services are completed. Development revenue in the form of milestone payments is recognized upon achievement of the related milestones and provided that collectability is reasonably assured and other revenue recognition criteria are met. Amounts received under cost reimbursement arrangements for production and research and development are recorded as offsets to the costs incurred and not recognized as revenue.
Distribution expenses	Distribution expenses: Costs invoiced to the Company by its third party logistics firm are classified as cost of goods sold in the consolidated statements of operations.
Shipping and handling costs	Shipping and handling costs: Amounts billed to customers for shipping and handling fees for the delivery of goods are classified as cost of goods sold in the consolidated statements of operations.
Research and development costs	Research and development costs: Research and development costs are charged to operations when incurred, include salaries and benefits, facilities costs, overhead costs, clinical trial costs, contract services, fees paid to regulatory authorities for review and approval of the Company's product candidates and other related costs, and are included in research and development in the consolidated statements of operations.
Income taxes	Income taxes: Income taxes are accounted for using the liability method, under which deferred taxes are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax laws that will be in effect when the differences are expected to reverse. Management evaluates the Company's tax positions in accordance with guidance on accounting for uncertainty in income taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not that the position will be sustained upon examination. As of December 31, 2015 and December 31, 2014, the Company had no uncertain tax positions that qualify for recognition in the consolidated financial statements. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.
Warrants	Warrants: The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company's balance sheet at their fair value on the date of issuance and prior to completion of the Company's IPO were revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company estimates the fair value of its derivative liabilities using third party valuation analysis that utilizes option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. Prior to the closing of the IPO, the Company's Series C warrants were determined to be derivative liabilities and they were revalued at each subsequent balance sheet date. Upon closing the IPO, the warrants issued in conjunction with the Series C financing were exchanged in a cashless exercise for 947,185 shares of Series C which converted into 78,926 shares of the Company's common stock. The remaining Series C warrants issued with the senior debt to purchase 170,000 pre-split shares of Series C ("Hercules Warrants") were converted into warrants to purchase 70,833 shares of the Company's common stock and the warrant liability was reclassified to Additional Paid in Capital within Stockholders' Equity (Deficit).
Share-based compensation	Share-based compensation: Share-based compensation awards, including grants of stock options to employees and directors and restricted stock and modifications to existing stock options, are recognized in the statement of operations based on their fair values. Compensation expense related to awards to employees is recognized on a straight-line basis, based on the grant date fair value, over the requisite service period of the award, which is generally the vesting term. The fair value of the Company's stock-based awards to employees and directors is estimated using the Black-Scholes option pricing model, which requires the input of and subjective assumptions, including (1) the expected stock price volatility, (2) the expected term of the award, (3) the risk-free interest rate and (4) expected dividends. Due to the previous lack of a public market for the trading of its common stock and a lack of company-specific historical and implied volatility data, prior to the IPO, the Company utilized third party valuation analyses to determine the fair value. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the actual expense recognized over the vesting period will only be for those options that vest.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
Concentration of credit risk	Concentration of credit risk: Accounts receivable subjects the Company to concentrations of credit risk. Four customers accounted for all the revenue in the year ended December 31, 2015 and two customers accounted for substantially all revenue in each of the years ended December 31, 2014 and 2013. Accounts receivable at December 31, 2015 and 2014 were due from three customers and one customer, respectively.
Segment information	Segment information: Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the development, manufacturing and commercialization of pharmaceuticals.
Liquidity	Liquidity: During 2015, 2014 and 2013, the Company produced operating losses and used cash to fund operations. Management intends to achieve profitability through revenue growth from pharmaceutical products developed with its extended-release technologies. The Company does not anticipate it will be profitable until after the launch of its approved product, Adzenys XR-ODT, or one or more of its ADHD product candidates. With the completion of the Company's IPO in July 2015, management believes the Company presently has sufficient liquidity to continue to operate for at least the next 12 months.
Application of revised accounting standards	Application of revised accounting standards: In April 2012, the Jumpstart Our Business Startups Act (the "JOBS Act"), was enacted in the United States. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period and, as a result, will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
Recent accounting pronouncements	Recent accounting pronouncements: In April 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update, ("ASU"), No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (topic 360); Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides additional requirements to classify a disposal of a component of an entity or a group of components of an entity in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company adopted this guidance in the first quarter of 2015, and the adoption of this standard did not have a material impact on the Company's financial statements. In May 2014, the FASB issued ASU, No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2018. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect the adoption of this standard will have a material impact on the Company's financial statements. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This ASU is for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company has performed the review required by this ASU and believes the Company presently has sufficient liquidity to continue to operate into the first quarter of 2016. On April 7, 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest—Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by this ASU. This ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The Company elected to early adopt this standard which did not have a material impact on the Company's financial position or results of operations. In July 2015, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2015-11, Inventory—Simplifying the Measurement of Inventory (Topic 330). The amendments in this ASU require an entity to measure inventory that is not measured using the last-in, first-out (LIFO) or retail inventory methods at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company is evaluating this ASU and has not determined the effect of this standard on its ongoing financial reporting. In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842) . Under the new guidance, lessees will be required recognize the following for all leases (with the exception of short-term leases) at the commencement date: 1) A lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and 2) A right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company is evaluating this ASU and has not determined the effect of this standard on its ongoing financial reporting. From time to time, additional new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
Reclassifications	Reclassifications: Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current period's presentation.
Subsequent events	Subsequent events: The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

Net loss per share (Tables)

Net loss per share (Tables)	12 Months Ended
	Dec. 31, 2015
Net loss per share
Potentially dilutive securities not included in the calculation of dilutive EPS	December 31, 2015 2014 2013 Series A Redeemable Convertible Preferred Stock (as converted) — Series B Redeemable Convertible Preferred Stock (as converted) — Series B-1 Redeemable Convertible Preferred Stock (as converted) — Series C Redeemable Convertible Preferred Stock (as converted) — Series C Redeemable Convertible Preferred Stock Warrants (as converted) — Common Stock Warrants Stock options

Fair value of financial instr32

Fair value of financial instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Methodologies and significant inputs used in the determination of the fair value
Hierarchy for financial instruments measured at fair value on a recurring basis	Fair Value as of December 31, 2015 Level 1 Level 2 Level 3 Total (in thousands) Cash and cash equivalents $ $ — $ — $ Earnout liability — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value as of December 31, 2014 (in thousands) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ $ — $ — $ Short term b investments — — Earnout liability — — Series C Redeemable Preferred Stock Warrants — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Changes in Level 3 liabilities measured at fair value	Earnout Liability Series C Warrants Issued With Senior Debt Series C Warrants Issued With Series C Redeemable Preferred Stock Financing (in thousands) Balance at December 31, 2013 $ — $ — $ — Additions during the period Changes in fair value — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2014 $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additions during the period — — Changes in fair value ) Warrants exercised — — ) Cashless warrant exercise due to IPO — — ) Conversion to common stock warrant — ) — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2015 $ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Earnout liability
Methodologies and significant inputs used in the determination of the fair value
Methodologies and significant inputs used in determination of fair value	Initial Valuation Earnout Liability December 31, 2014 Earnout Liability December 31, 2015 Earnout Liability (Dollars in thousands) Date of Valuation 8/28/2014 12/31/2014 12/31/2015 Valuation Method Monte Carlo Monte Carlo Monte Carlo Volatility (annual) 50% 50% 50% Risk-free rate (annual) .03% - 3.56% .15% - 3.21% .56% - 3.31% Time period from valuation until end of earnout .1708 - 9.8417 .5 - 9.5 .5 - 9.5 Earnout Target 1 $13,700 $13,700 $13,700 Earnout Target 2 $18,200 $18,200 $18,200 Discount rate 8.03% - 10.51% 7.96% - 11.03% 8.11% - 10.86% ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $589 $756 $214
Series C Warrants Issued with Senior Debt
Methodologies and significant inputs used in the determination of the fair value
Methodologies and significant inputs used in determination of fair value	Series C Warrants Issued With March 28, 2014 Senior Debt Series C Warrants Issued With September 25, 2014 Senior Debt Revalue Series C Warrants Issued with Senior Debt at December 31, 2014 Revalue Series C Warrants Issued with Senior Debt at July 22, 2015 (Dollars in thousands, except $5 and $12 Exercise Prices) Date of Valuation 3/28/2014 9/25/2014 12/31/2014 7/22/2015 Valuation Method Black-Scholes-Merton PWERM and Black-Scholes-Merton PWERM and Option Pricing Black-Scholes-Merton Option-Pricing Dividend yield (per share) 0 0 0 0 Exercise price $5 $5 $5 $12 Volatility (annual) 60% 60% 60% 60% Risk-free rate (annual) 0.34% 2.03% .25% - 2.47% 1.78% Contractual term (years) 1.76 5.76 1 - 5 5 Number of warrants 60,000 110,000 170,000 70,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $124 $248 $454 $611 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Series C Warrants Issued with Series C Redeemable Preferred Stock Financing | Derivative liability
Methodologies and significant inputs used in the determination of the fair value
Methodologies and significant inputs used in determination of fair value	Initial Valuation of December 31, 2014 Warrants Issued With Series C Redeemable Preferred Stock Initial Valuation of January 2015 Warrants Issued With Series C Redeemable Preferred Stock Initial Valuation of February 2015 Warrants Issued With Series C Redeemable Preferred Stock Revalue All Warrants Issued With Series C Redeemable Preferred Stock at July 22, 2015 (Dollars in thousands, except $5 and $12 Exercise Prices) Date of Valuation 12/31/2014 1/31/2015 2/28/2015 7/22/2015 Valuation Method PWERM and Option Pricing PWERM and Option Pricing PWERM and Option Pricing Intrinsic Value Dividend yield (per share) 0 0 0 0 Exercise price $5 $5 $5 $12 Volatility (annual) 60% 60% 60% — Risk-free rate (annual) .25% - 2.47% .25% - 2.47% .25% - 2.47% — Contractual term (years) 1 - 5 1 - 5 1 - 5 — Number of warrants 749,967 590,906 606,312 1,347,185 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of liability at valuation date $1,335 $1,052 $1,079 $4,042 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventories
Schedule of Inventory	December 31, 2015 2014 (in thousands) Raw materials $ $ Work in progress Finished goods ​ ​ ​ ​ ​ ​ ​ ​ Inventory at cost Inventory reserve ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property and equipment
Schedule of property and equipment	December 31, 2015 2014 (in thousands) Assets under capital lease $ $ Leasehold improvements Manufacturing, packaging and lab equipment Office furniture and equipment Assets under construction ​ ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation and amortization (including $3,684 and $2,317 at December 31, 2015 and 2014, respectively, applicable to capital leases) ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Sale-leaseback transaction (Tab

Sale-leaseback transaction (Tables)	12 Months Ended
	Dec. 31, 2015
Sale-leaseback transaction
Summary of sale-leaseback transactions	Leases 1 & 2 February 2013 Lease 3 July 2013 Lease 4 November 2013 Lease 5 March 2014 Total (in thousands) Capitalization of leased assets $ $ $ $ — $ 2013 Amortization ) ) ) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2013 — 2014 Capitalization of leased assets Assets retired in 2014 ) — — — ) 2014 Amortization ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2014 $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets retired in 2015 ) — ) — ) 2015 Amortization ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying value at December 31, 2015 $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2015
Intangible assets, net
Schedule of finite lived intangible assets	December 31, 2015 2014 (in thousands) Proprietary modified-release drug delivery technology $ $ Tussionex ANDA CPI profit sharing Other ​ ​ ​ ​ ​ ​ ​ ​ Accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of aggregate amortization of intangible assets	Year ending December 31: December 31, 2015 (in thousands) 2016 $ 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Dec. 31, 2015
Other assets
Schedule of Other assets	December 31, 2015 2014 (in thousands) Patents $ $ Deposits ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes
Schedule of significant components of deferred income tax assets and liabilities	December 31, 2015 2014 (in thousands) Deferred Tax Assets: Net operating losses $ $ Accrued Expenses Inventory Share-based Compensation R&D tax credit Deferred lease liability Property and equipment Earnout Liability Deferred Gain on Sale Leaseback Litigation Costs Allowances ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets Deferred Tax Liabilities: Inventory Reserve ) — Capital lease liability ) ) Intangible assets ) ) State Deferreds ) — ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) Valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax asset (liability) $ — $ — ​ ​ ​ ​ ​ ​ ​ ​
Schedule of Unrecognized Tax Benefits Roll Forward	December 31, 2015 2014 (in thousands) Beginning Balance $ $ — Increase/(Decrease) based on tax positions taken during a prior period — — Increase/(Decrease) based on tax positions taken during the current period ​ ​ ​ ​ ​ ​ ​ ​ Ending Balance $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of reconciliation of Federal statutory tax rate	December 31, 2015 2014 U.S. Statutory Tax Rate % % R&D Credit % % Change in Valuation Allowance )% )% Deferred Tax Adjustments )% % Provision to Return and Other Adjustments )% % ​ ​ ​ ​ ​ ​ ​ ​ Tax Expense/(Benefit) % % ​ ​ ​ ​ ​ ​ ​ ​

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
	Dec. 31, 2015
Long-term debt.
Schedule of long-term debt	December 31, 2015 2014 (in thousands) Senior debt, net of discount of $1,167 and $1,743 $ $ 10% subordinated note payable to a related party Capital leases, maturing through August 2017 ​ ​ ​ ​ ​ ​ ​ ​ Less current portion ) ) ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of future minimum capital lease payments	Year ending: December 31, (in thousands) 2016 $ 2017 ​ ​ ​ ​ ​ Total minimum lease payments Less amount representing interest ​ ​ ​ ​ ​ Future minimum lease payments $ ​ ​ ​ ​ ​
Schedule of future principal payments of long-term debt, including capital leases	Year ending: December 31, 2015 (in thousands) 2016 $ 2017 ​ ​ ​ ​ ​ Future principal payments $ ​ ​ ​ ​ ​ Less unamortized debt discount ) Less current portion of long-term debt ) ​ ​ ​ ​ ​ Total long-term debt $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Common stock and redeemable c40

Common stock and redeemable convertible preferred stock (Tables)	12 Months Ended
	Dec. 31, 2015
Common stock and redeemable convertible preferred stock
Summary of authorized, issued and outstanding shares by class of stock	December 31, 2015 December 31, 2014 Authorized Shares Issued and Outstanding Shares Authorized Shares Issued and Outstanding Shares Common Stock Preferred Stock — — — Series A Preferred Stock — — Series B Preferred Stock — — Series B-1 Preferred Stock — — Series C Preferred Stock — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Shares Issued ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Treasury Stock ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Outstanding Shares ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Authorized Shares

Stock options, restricted sto41

Stock options, restricted stock and performance stock options (Tables)	12 Months Ended
	Dec. 31, 2015
Stock options, restricted stock and performance stock options
Schedule of weighted-average key assumptions used in determining fair value of options granted	Year Ended December 31, 2015 2014 2013 Estimated dividend yield % % % Expected stock price volatility % % % Weighted-average risk-free interest rate % % % Expected life of option in years Weighted-average option fair value at grant $ $ $
Summary of outstanding and exercisable options	Number of Options Weighted- Average Exercise Price Intrinsic Value (in thousands) Outstanding at January 1, 2013 $ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2013 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2013 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2014 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2014 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Exercised ) Expired, forfeited or cancelled ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2015 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at December 31, 2015 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of status of nonvested restricted stock	Number of Shares Weighted- Average Grant Date Fair Value Nonvested at January 1, 2013 $ Granted Vested ) Forfeited ) ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at January 1, 2014 $ Granted — — Vested ) Forfeited — — ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted — — Vested ) Forfeited — — ​ ​ ​ ​ ​ ​ ​ ​ Nonvested at December 30, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and contingencies
Schedule of minimum lease payments	Year ending December 31, (in thousands) 2016 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ Future minimum lease payments $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued operations
Schedule of components of discontinued operations	2013 (in thousands) Revenue $ Direct costs Impairment of intangible assets ​ ​ ​ ​ ​ Net loss from discontinued operations $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Selected Quarterly Financial 44

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2015
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data	Quarter Ended March 31, 2014 June 30, 2014 September 30, 2014 December 31, 2014 Net Sales $ $ $ ) $ Gross loss ) ) ) ) Net Loss $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock Accretion to Redemption Value ) ) ) ) Preferred Stock Dividends ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stock $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute net loss per share, basic and diluted(2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share of common stock, basic and diluted(1): $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 Net Sales $ $ $ $ Gross loss ) ) ) ) Net Loss $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock Accretion to Redemption Value ) ) ) — Preferred Stock Dividends ) ) ) — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss attributable to common stock $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute net loss per share, basic and diluted(2)(3) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share of common stock, basic and diluted(1): $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly loss per share may not necessarily equal the total for the year. (2) In connection with the IPO, the Company's Board of Directors approved a 1-for-2.4 reverse stock split of the Company's common stock which also resulted in a proportional adjustment to the conversion ratios of the preferred stock and the preferred stock warrants. All references to common stock and per share amounts in these condensed financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split. (3) Between June 30, 2015 and July 27, 2015, the Company issued a total of 1,000,000 shares of its Series C redeemable convertible preferred stock to several existing investors upon the exercise of warrants to purchase Series C preferred stock held by those investors at an exercise price of $5.00 per share, for an aggregate exercise price of $5.0 million. On the IPO closing date, all outstanding shares of redeemable preferred stock converted into 9,217,983 shares of common stock and all remaining outstanding Series C warrants issued in conjunction with purchases of Series C preferred stock were net exercised at the IPO price for 78,926 shares of common stock. Upon the closing of the Company's IPO, all of the shares of the Company's redeemable convertible preferred stock were retired and cancelled and shall not be reissued as shares of such series, and all rights and preferences of those Preferred Shares were cancelled including the right to receive undeclared accumulated dividends. On July 28, 2015, the Company closed its initial public offering whereby the Company sold 5,520,000 shares of common stock, at a public offering price of $15.00 per share, which includes 720,000 shares of common stock resulting from the underwriters' exercise of their over-allotment option at the IPO price on July 23, 2015. These transactions produced a significant increase in the number of shares outstanding which will impact the year-over-year comparability of the Company's loss per share calculations.

Organization and nature of op45

Organization and nature of operations - Organization (Details)	12 Months Ended
	Dec. 31, 2015item
Organization and nature of operations
Number of approved products	1
Number of proprietary product candidates	2

Organization and nature of op46

Organization and nature of operations - IPO (Details) $ / shares in Units, $ in Millions	Jul. 28, 2015USD ($)$ / sharesshares	Jul. 10, 2015	Jul. 27, 2015USD ($)$ / sharesshares	Dec. 31, 2015$ / sharesshares
Series C preferred stock
Organization and nature of operations
Public offering price (in dollars per share) | $ / shares				$ 5
Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Organization and nature of operations
Number of shares issued upon exercise of warrants			1,000,000
Exercise price of warrants (in dollars per share) | $ / shares			$ 5
Proceeds from exercise of warrants (in dollars) | $			$ 5
Common Stock
Organization and nature of operations
Reverse stock split ratio		0.4167
Common Stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing | Cashless exercise of redeemable convertible preferred stock warrant into common stock
Organization and nature of operations
Shares issued on conversion	78,926
Common Stock | All series of redeemable convertible preferred stock | Conversion of redeemable convertible preferred stock into common stock
Organization and nature of operations
Shares issued on conversion	9,217,983
IPO | Common Stock
Organization and nature of operations
Net proceeds from issuance of common stock (in shares)	5,520,000			5,520,000
Public offering price (in dollars per share) | $ / shares	$ 15
Net proceeds from issuance of stock | $	$ 75
Over-allotment option | Common Stock
Organization and nature of operations
Net proceeds from issuance of common stock (in shares)	720,000

Organization and nature of op47

Organization and nature of operations - Authorized Shares (Details) - shares	Dec. 31, 2015	Jul. 28, 2015	Dec. 31, 2014
Organization and nature of operations
Common Stock, Shares Authorized	100,000,000	100,000,000	35,000,000
Preferred Stock, Shares Authorized	5,000,000	5,000,000	0

Summary of significant accoun48

Summary of significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2015USD ($)subsidiary	Dec. 31, 2014USD ($)subsidiary	Dec. 31, 2013USD ($)	Sep. 16, 2015subsidiary	Jun. 29, 2015	Oct. 06, 2014USD ($)
Significant accounting policies disclosures
Allowance for Doubtful Accounts	$ 0	$ 0
Impairment charges	0	0
Discontinued operations, impairment charges			$ 544,000
Liability for uncertain tax positions	$ 0	$ 0
Wholly-owned subsidiaries
Significant accounting policies disclosures
Number of wholly-owned subsidiaries | subsidiary	4	2
Number of new wholly-owned subsidiaries established | subsidiary				2
Percentage ownership by parent (as a percent)		100.00%
Neostx, Inc. ("NTX")
Significant accounting policies disclosures
Percentage ownership by parent (as a percent)		99.90%
Minimum
Significant accounting policies disclosures
Property, Plant and Equipment, Useful Life	3 years
Intangible asset - useful life	10 years
Maximum
Significant accounting policies disclosures
Property, Plant and Equipment, Useful Life	10 years
Intangible asset - useful life	20 years
Neostx, Inc. ("NTX")
Significant accounting policies disclosures
Ownership acquired (as a percent)					0.10%
Third party logistics provider - 3PL
Significant accounting policies disclosures
Inventory labeled as Schedule III controlled substance that is solely located at the third party logistics provider (does not include inventory at wholesalers)						$ 0

Summary of significant accoun49

Summary of significant accounting policies - Warrants (Details)	Jul. 28, 2015shares
Series C Warrants Issued with Senior Debt | Conversion of redeemable convertible preferred stock warrant into common stock warrant
Organization and nature of operations
Warrants issued (in shares)	170,000
Common Stock Warrant | Conversion of redeemable convertible preferred stock warrant into common stock warrant
Organization and nature of operations
Number of warrants converted into other warrants	70,833
Common Stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing | Cashless exercise of redeemable convertible preferred stock warrant into common stock
Organization and nature of operations
Shares converted	947,185
Shares issued on conversion	78,926

Summary of significant accoun50

Summary of significant accounting policies - Credit Risk (Details) - customer	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of significant accounting policies
Number Of Customers Accounting For Substantially All Or All Revenues	4	2	2
Number Of Customers Accounting For All Accounts Receivable	3	1

Summary of significant accoun51

Summary of significant accounting policies - Segment Information and Liquidity (Details)	12 Months Ended
	Dec. 31, 2015segmentproduct
Summary of significant accounting policies
Number of Operating Segments | segment	1
Minimum Number Of Product Candidate Launches Anticipated Before Profitability Anticipated | product	1

Net loss per share (Details)

Net loss per share (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Series A preferred stock
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)		487,494	487,494
Series B preferred stock
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)		1,297,100	1,297,100
Series B-1 preferred stock
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)		2,275,733	2,275,733
Series C preferred stock
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)		3,647,274	2,194,569
Warrants | Series C Redeemable Convertible Preferred Stock Warrants
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)	70,833	383,316
Warrants | Common Stock Warrant
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)	50,158	337,133	337,133
Employee stock options
Net loss per share disclosures
Potentially dilutive shares not included in the calculation of diluted EPS (as converted if related to warrants or redeemable convertible preferred stock)	1,352,283	511,775	326,062

Fair value of financial instr53

Fair value of financial instruments - Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Hierarchy for financial instruments measured at fair value on a recurring basis
Short term investments		$ 3,000
Earnout liability	$ 214	756
Recurring basis | Fair Value
Hierarchy for financial instruments measured at fair value on a recurring basis
Cash and cash equivalents	90,763	13,343
Short term investments		3,000
Earnout liability	214	756
Total assets and liabilities	90,977	18,888
Recurring basis | Fair Value | Series C Redeemable Convertible Preferred Stock Warrants
Hierarchy for financial instruments measured at fair value on a recurring basis
Series C Redeemable Preferred Stock Warrants		1,789
Recurring basis | Fair Value | Level 1
Hierarchy for financial instruments measured at fair value on a recurring basis
Cash and cash equivalents	90,763	13,343
Short term investments		3,000
Total assets and liabilities	90,763	16,343
Recurring basis | Fair Value | Level 3
Hierarchy for financial instruments measured at fair value on a recurring basis
Earnout liability	214	756
Total assets and liabilities	$ 214	2,545
Recurring basis | Fair Value | Level 3 | Series C Redeemable Convertible Preferred Stock Warrants
Hierarchy for financial instruments measured at fair value on a recurring basis
Series C Redeemable Preferred Stock Warrants		$ 1,789

Fair value of financial instr54

Fair value of financial instruments - Hercules Warrants (Details) - Series C Warrants Issued with Senior Debt - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2015	Sep. 25, 2014	Mar. 28, 2014	Jul. 22, 2015	Dec. 31, 2014	Dec. 31, 2015
Methodologies and significant inputs used in the determination of the fair value
Number of warrants (in shares)						0
Conversion of redeemable convertible preferred stock warrant into common stock warrant
Methodologies and significant inputs used in the determination of the fair value
Contractual term	5 years
Recurring basis | Level 3 | Derivative liability | Black-Scholes-Merton
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)			$ 0
Exercise price (in dollars per share)			$ 5
Volatility (as a percent)			60.00%
Risk-free rate (as a percent)			0.34%
Contractual term			1 year 9 months 4 days
Number of warrants (in shares)			60,000
Fair value of liability at valuation date			$ 124
Recurring basis | Level 3 | Derivative liability | Probability-Weighted Expected Return and Black-Scholes-Merton
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)		$ 0
Exercise price (in dollars per share)		$ 5
Volatility (as a percent)		60.00%
Risk-free rate (as a percent)		2.03%
Contractual term		5 years 9 months 4 days
Number of warrants (in shares)		110,000
Fair value of liability at valuation date		$ 248
Recurring basis | Level 3 | Derivative liability | Probability-Weighted Expected Return and Option Pricing
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)					$ 0
Exercise price (in dollars per share)					$ 5
Volatility (as a percent)					60.00%
Number of warrants (in shares)					170,000
Fair value of liability at valuation date					$ 454
Recurring basis | Level 3 | Derivative liability | Probability-Weighted Expected Return and Option Pricing | Minimum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)					0.25%
Contractual term					1 year
Recurring basis | Level 3 | Derivative liability | Probability-Weighted Expected Return and Option Pricing | Maximum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)					2.47%
Contractual term					5 years
Recurring basis | Level 3 | Derivative liability | Black-Scholes-Merton Option-Pricing
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)				$ 0
Exercise price (in dollars per share)	$ 12			$ 12
Volatility (as a percent)				60.00%
Risk-free rate (as a percent)				1.78%
Contractual term				5 years
Number of warrants (in shares)	70,833			70,833
Fair value of liability at valuation date	$ 611			$ 611

Fair value of financial instr55

Fair value of financial instruments - Series C Warrants (Details) - Recurring basis - Level 3 - Derivative liability - Series C Warrants Issued with Series C Redeemable Preferred Stock Financing - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	2 Months Ended	7 Months Ended	12 Months Ended
	Jan. 31, 2015	Feb. 28, 2015	Jul. 22, 2015	Dec. 31, 2014
Probability-Weighted Expected Return and Option Pricing
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)	$ 0	$ 0		$ 0
Exercise price (in dollars per share)	$ 5	$ 5		$ 5
Volatility (as a percent)	60.00%	60.00%		60.00%
Number of warrants (in shares)	590,906	606,312		749,967
Fair value of liability at valuation date	$ 1,052	$ 1,079		$ 1,335
Probability-Weighted Expected Return and Option Pricing | Minimum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)	0.25%	0.25%		0.25%
Contractual term	1 year	1 year		1 year
Probability-Weighted Expected Return and Option Pricing | Maximum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)	2.47%	2.47%		2.47%
Contractual term	5 years	5 years		5 years
Intrinsic Value
Methodologies and significant inputs used in the determination of the fair value
Dividend yield (in dollars per share)			$ 0
Exercise price (in dollars per share)			$ 12
Number of warrants (in shares)			1,347,185
Fair value of liability at valuation date			$ 4,042

Fair value of financial instr56

Fair value of financial instruments - Earnout Liability (Details) - Recurring basis - Level 3 - Earnout liability - Monte Carlo - USD ($) $ in Thousands	Aug. 28, 2014	Dec. 31, 2015	Dec. 31, 2014
Methodologies and significant inputs used in the determination of the fair value
Volatility (as a percent)	50.00%	50.00%	50.00%
Earnout Target 1	$ 13,700	$ 13,700	$ 13,700
Earnout Target 2	18,200	18,200	18,200
Fair value of liability at valuation date	$ 589	$ 214	$ 756
Minimum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)	0.03%	0.56%	0.15%
Time period from valuation until end of earnout	2 months 2 days	6 months	6 months
Discount rate	8.03%	8.11%	7.96%
Maximum
Methodologies and significant inputs used in the determination of the fair value
Risk-free rate (as a percent)	3.56%	3.31%	3.21%
Time period from valuation until end of earnout	9 years 10 months 3 days	9 years 6 months	9 years 6 months
Discount rate	10.51%	10.86%	11.03%

Fair value of financial instr57

Fair value of financial instruments - Changes in Level 3 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Earnout liability
Changes in Level 3 liabilities measured at fair value
Balance at beginning of year	$ 756
Additions		$ 589
Changes in fair value	(542)	167
Balance at end of period	214	756
Derivative liability | Series C Warrants Issued with Senior Debt
Changes in Level 3 liabilities measured at fair value
Balance at beginning of year	454
Additions		372
Changes in fair value	157	82
Conversion to common stock warrant	(611)
Balance at end of period		454
Derivative liability | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Changes in Level 3 liabilities measured at fair value
Balance at beginning of year	1,335
Additions	2,131	1,335
Changes in fair value	1,698	0
Warrants exercised	(2,322)
Cashless warrant exercise due to IPO	$ (2,842)
Balance at end of period		$ 1,335

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventories
Raw materials	$ 1,211	$ 646
Work in progress	175	82
Finished Goods	1,189	1,499
Inventory at cost	2,575	2,227
Inventory reserve	(55)	(196)
Inventories net	$ 2,520	$ 2,031

Property and equipment (Details

Property and equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and equipment disclosures
Property and equipment gross	$ 11,170,000	$ 10,181,000
Accumulated depreciation and amortization	(6,046,000)	(4,350,000)
Property and equipment, net	5,124,000	5,831,000
Accumulated depreciation and amortization of capital lease	3,684,000	2,317,000
Depreciation and amortization expense	1,724,000	1,645,000	$ 1,330,000
Assets under capital leases
Property and equipment disclosures
Property and equipment gross	6,241,000	6,271,000
Leasehold improvements
Property and equipment disclosures
Property and equipment gross	3,497,000	3,388,000
Manufacturing, packaging and lab equipment
Property and equipment disclosures
Property and equipment gross	874,000	189,000
Office furniture and equipment
Property and equipment disclosures
Property and equipment gross	314,000	118,000
Assets under construction
Property and equipment disclosures
Property and equipment gross	244,000	215,000
Temporarily Idle Equipment
Property and equipment disclosures
Property and equipment gross	1,699,000	1,728,000
Accumulated depreciation and amortization of capital lease	$ 1,396,000	$ 925,000

Sale-leaseback transaction (Det

Sale-leaseback transaction (Details)	1 Months Ended	12 Months Ended			14 Months Ended
	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2014tranche	Dec. 31, 2012USD ($)
Sale-leaseback transaction disclosures
Proceeds from sale of assets	$ 795,000			$ 5,500,000
Number of tranches | tranche					5
Deferred gain			$ 116,000	2,700,000
Lease term		42 months
Net deferred gain recognized in period on sale leaseback transaction		$ 831,000	824,000	601,000
Sale-leaseback transaction activity
Carrying value, beginning of period		3,954,000	4,542,000
Capitalization of leased assets			795,000	5,500,000
Assets retired		(30,000)	(24,000)
Amortization		(1,367,000)	(1,359,000)	(958,000)
Carrying value, end of period		2,557,000	3,954,000	4,542,000
Capital leases
Sale-leaseback transaction disclosures
Related Party Maximum Sale And Leaseback Transaction Amount						$ 6,500,000
Leases 1 and 2
Sale-leaseback transaction activity
Carrying value, beginning of period		1,613,000	2,625,000
Capitalization of leased assets				3,500,000
Assets retired		(28,000)	(24,000)
Amortization		(969,000)	(988,000)	(875,000)
Carrying value, end of period		616,000	1,613,000	2,625,000
Lease 3
Sale-leaseback transaction activity
Carrying value, beginning of period		792,000	935,000
Capitalization of leased assets				1,000,000
Amortization		(143,000)	(143,000)	(65,000)
Carrying value, end of period		649,000	792,000	935,000
Lease 4
Sale-leaseback transaction activity
Carrying value, beginning of period		839,000	982,000
Capitalization of leased assets				1,000,000
Assets retired		(2,000)
Amortization		(141,000)	(143,000)	(18,000)
Carrying value, end of period		696,000	839,000	$ 982,000
Lease 5
Sale-leaseback transaction activity
Carrying value, beginning of period		710,000
Capitalization of leased assets			795,000
Amortization		(114,000)	(85,000)
Carrying value, end of period		$ 596,000	$ 710,000

Intangible assets (Details)

Intangible assets (Details) - USD ($)	Aug. 28, 2014	Jun. 15, 2009	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible assets disclosures
Intangible assets, excluding patents, gross			$ 22,756,000	$ 22,756,000
Accumulated amortization			(6,084,000)	(4,589,000)
Intangible assets, excluding patents, net			16,672,000	18,167,000
Amortization of intangible assets			1,495,000	1,037,000	$ 842,000
Payment made to acquire asset				6,283,000
Discontinued operations, impairment charges					544,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity
2,016			1,496,000
2,017			1,496,000
2,018			1,496,000
2,019			1,496,000
2,020			1,496,000
Thereafter			9,192,000
Finite lived intangible assets, net			16,672,000
Proprietary modified-release drug delivery technology
Intangible assets disclosures
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 15,600,000
Intangible assets, excluding patents, gross			15,600,000	15,600,000
Useful life		20 years
Amortization of intangible assets			780,000	780,000	$ 780,000
Tussionex ANDA
Intangible assets disclosures
Intangible assets, excluding patents, gross			4,829,000	4,829,000
Payment made to acquire asset	$ 4,200,000
Legal fees	90,000
Earnout fair value	589,000
Tussionex ANDA | Other income (expense)
Intangible assets disclosures
Increase (decrease) in fair value of earnout liability			(542,000)	167,000
CPI Profit Sharing
Intangible assets disclosures
Intangible assets, excluding patents, gross			2,043,000	2,043,000
Payment made to acquire asset	2,000,000
Legal fees	$ 43,000
Other
Intangible assets disclosures
Intangible assets, excluding patents, gross			284,000	284,000
Tussionex ANDA and CPI profit sharing
Intangible assets disclosures
Useful life	10 years
Amortization of intangible assets			$ 687,000	$ 229,000

Other assets (Details)

Other assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Other assets disclosures
Patents for product candidates	$ 2,273,000	$ 2,051,000
Deposits	197,000	176,000
Other assets	2,470,000	2,227,000
Amortization of patents	23,000	$ 31,000
Generic Tussionex product
Other assets disclosures
Patents being amortized	$ 231,000
Useful life	10 years

Income Taxes - Deferred Taxes (

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets
Net operating losses	$ 37,809	$ 29,325
Accrued Expenses	317	392
Inventory	0	67
Share-based Compensation	388	76
R&D tax credit	1,660	2,029
Deferred lease liability	396	404
Property and equipment	581	518
Earnout Liability	73	200
Deferred Gain on Sale Leaseback	186	476
Litigation Costs	714	776
Allowances	623	181
Total deferred tax assets	42,747	34,444
Deferred Tax Liabilities
Inventory Reserve	(19)
Capital lease liability	(603)	(560)
Intangible assets	(3,763)	(3,990)
State Deferreds	(31)
Total deferred tax liabilities	(4,416)	(4,550)
Valuation allowance	(38,331)	(29,894)
Net deferred tax asset (liability)	$ 0	$ 0

Income Taxes - Tax Carryforward

Income Taxes - Tax Carryforwards and Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Unrecognized tax benefits disclosures
Accrued interest related to uncertain tax positions	$ 0	$ 0
Rollforward of gross unrecognized tax benefits
Beginning Balance	835,000
Increase based on tax positions taken during the current period	3,520,000	835,000
Ending Balance	4,355,000	835,000
Federal
Tax Carryforwards And Uncertainties [Line Items]
Operating Loss Carryforwards	122,075,000	86,551,000
Net operating loss carryforward that will expire unused	6,089,000
State
Tax Carryforwards And Uncertainties [Line Items]
Operating Loss Carryforwards	278,000	0
Research and development credits
Tax Carryforwards And Uncertainties [Line Items]
Tax Credit Carryforward, Amount	2,010,000	$ 2,029,000
Research and development credits | Federal
Tax Carryforwards And Uncertainties [Line Items]
Tax credit carryforwards that will expire unused	$ 350,000

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes
Increase in Valuation Allowance	$ 8,437,000	$ 8,436,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Tax Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes
Statutory Tax Rate	34.00%	34.00%
R&D Credit	0.00%	2.00%
Change in Valuation Allowance	(26.00%)	(41.00%)
Deferred Tax Adjustments	(7.00%)	0.00%
Provision to Return and Other Adjustments	(1.00%)	5.00%
Tax Expense / (Benefit)	0.00%	0.00%

Long-term debt - Summary (Detai

Long-term debt - Summary (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Long-term debt disclosures
Long-term debt and capital lease obligations, including current maturities	$ 34,244	$ 24,774
Less current portion	(7,973)	(1,653)
Long-term debt, net of current portion	26,271	23,121
Unamortized discount on debt	1,167
Senior debt
Long-term debt disclosures
Long-term debt and capital lease obligations, including current maturities	24,895	14,320
Unamortized discount on debt	1,167	1,743
10% subordinated note payable | Essex Capital Corporation, as Investor
Long-term debt disclosures
Long-term debt and capital lease obligations, including current maturities	6,994	6,446
Capital leases
Long-term debt disclosures
Long-term debt and capital lease obligations, including current maturities	$ 2,355	$ 4,008

Long-term debt - Senior Debt (D

Long-term debt - Senior Debt (Details)	Jul. 22, 2015$ / sharesshares	Jun. 10, 2015USD ($)	Mar. 13, 2015USD ($)	Sep. 25, 2014USD ($)tranche$ / sharesshares	Mar. 28, 2014USD ($)tranche$ / sharesshares	Aug. 20, 2012USD ($)	May. 31, 2016	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Long-term debt disclosures
Draws from senior debt								$ 10,000,000	$ 15,000,000
Interest paid								2,524,000	1,793,000	$ 1,324,000
Fair value of warrants									1,789,000
Hercules LSA | Series C Warrants Issued with Senior Debt | Other income (expense)
Long-term debt disclosures
Fair value adjustment of warrants (reduction) increase								157,000
Senior debt | Credit Agreement | Term Loan
Long-term debt disclosures
Debt term						4 years
Maximum borrowing capacity per agreement						$ 10,000,000
Interest rate (as a percent)						9.50%
Fee payable at maturity						$ 250,000
Repayment of outstanding amount					$ 10,000,000
Interest paid					697,000
Gains (losses) on early prepayment					(445,000)
Prepayment penalty					98,000
Write-off of unamortized exit fee					154,000
Write-off of unamortized loan cost					193,000
Senior debt | Hercules LSA
Long-term debt disclosures
Maximum borrowing capacity per agreement				$ 25,000,000	$ 20,000,000
Increase In Maximum Borrowing Capacity				$ 5,000,000
Number of draws available per debt agreement | tranche					2
Number of additional draws available per amendment | tranche				2
End of term charge, as a percentage of amount drawn					4.25%
End of term charge				$ 1,062,500	$ 850,000			1,100,000
Term of interest and principal payments, which commence at a later date							30 months
End of term charge amortization total								311,000	128,000
Debt discount amortization								$ 265,000	$ 140,000
Senior debt | Hercules LSA | Tranche 1
Long-term debt disclosures
Interest rate (as a percent)					9.00%
Draws from senior debt					$ 10,000,000
Residual proceeds allocation					$ 9,876,000
Senior debt | Hercules LSA | Tranche 1 | Series C Warrants Issued with Senior Debt
Long-term debt disclosures
Warrants issued (in shares) | shares					60,000
Current price (in dollars per share) | $ / shares					$ 5
Fair value of warrants					$ 124,000
Senior debt | Hercules LSA | Tranche 2
Long-term debt disclosures
Interest rate (as a percent)				10.50%
Draws from senior debt				$ 5,000,000
Residual proceeds allocation				$ 4,752,000
Senior debt | Hercules LSA | Tranche 2 | Series C Warrants Issued with Senior Debt
Long-term debt disclosures
Current price (in dollars per share) | $ / shares					$ 5
Warrants provided for but not issued (in shares) | shares					60,000
Senior debt | Hercules LSA | Tranche 2 | Series C preferred stock | Series C Warrants Issued with Senior Debt
Long-term debt disclosures
Warrants issued (in shares) | shares				110,000
Current price (in dollars per share) | $ / shares				$ 5
Fair value of warrants				$ 248,000
Senior debt | Hercules LSA | Tranche 3
Long-term debt disclosures
Interest rate (as a percent)			10.50%
Draws from senior debt			$ 5,000,000
Senior debt | Hercules LSA | Tranche 4
Long-term debt disclosures
Interest rate (as a percent)		9.00%
Draws from senior debt		$ 5,000,000
Senior debt | Hercules LSA | Tranches 2 - 4
Long-term debt disclosures
Remaining borrowing capacity				$ 15,000,000
Number of remaining draws available | tranche				3
Amount of each remaining draw available				$ 5,000,000
Senior debt | Hercules LSA | Tranches 2 and 3
Long-term debt disclosures
Interest rate (as a percent)				10.50%
Conversion, initial public offering | Common Stock Warrant
Long-term debt disclosures
Number of warrants converted into other warrants | shares	70,833
Conversion price (in dollars per share) | $ / shares	$ 12

Long-term debt - Subordinated R

Long-term debt - Subordinated Related Party Note (Details) - 10% subordinated note payable - Essex Capital Corporation, as Investor - USD ($)	Jul. 21, 2014	Jun. 28, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011
Long-term debt disclosures
Interest rate (as a percent)			10.00%
Aggregate principal amount			$ 5,935,000	$ 5,935,000	$ 5,900,000
Reduced interest rate per amendment to note (as a percent)		6.00%
Payment for legal settlement	$ 128,000
Interest accrued			$ 1,059,000	$ 511,000

Long-term debt - Capital Lease

Long-term debt - Capital Lease Obligations to Related Party (Details) - Capital leases - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Long-term debt disclosures
Existing assets under sale-leaseback transaction			$ 5,500,000
Newly acquired assets under sale-leaseback transaction				$ 795,000
Imputed interest rate on lease (as a percent)	14.50%
Interest expense	$ 467,000	$ 662,000	$ 474,000

Long-term debt - Future Minimum

Long-term debt - Future Minimum Capital Lease Payments (Details) $ in Thousands	Dec. 31, 2015USD ($)
Future minimum capital lease payments
2,016	$ 2,124
2,017	473
Total minimum lease payments	2,597
Less amount representing interest	242
Future minimum lease payments	$ 2,355

Long-term debt - Future Princip

Long-term debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Future principal payments of long-term debt, including capital leases
2,016	$ 7,973
2,017	27,438
Future principal payments, including capital leases	35,411
Less unamortized debt discount	(1,167)
Less current portion of long-term debt	(7,973)	$ (1,653)
Long-term debt, net of current portion	$ 26,271	$ 23,121

Common stock and redeemable c73

Common stock and redeemable convertible preferred stock - Summary (Details) - $ / shares	Dec. 31, 2015	Jul. 28, 2015	Dec. 31, 2014
Par value disclosures
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, par value (in dollars per share)	0.001	$ 0.001	0.001
Redeemable preferred stock, par value (in dollars per share)	$ 0.001		$ 0.001
Authorized Shares
Common stock, authorized shares	100,000,000	100,000,000	35,000,000
Preferred stock, authorized shares	5,000,000	5,000,000	0
Total Authorized Shares	105,000,000		62,500,000
Issued Shares
Common stock, issued shares	16,025,155		938,859
Preferred Stock, issued shares	0		0
Total Issued Shares	16,025,155		19,437,307
Treasury Stock	(9,197)		(55,905)
Outstanding Shares
Common stock, outstanding shares	16,015,958		882,954
Preferred stock, outstanding shares	0		0
Total Outstanding Shares	16,015,958		19,381,402
Series A preferred stock
Authorized Shares
Redeemable preferred stock, authorized shares	0		1,170,000
Issued Shares
Redeemable preferred stock, issued shares	0		1,170,000
Outstanding Shares
Redeemable preferred stock, outstanding shares	0		1,170,000
Series B preferred stock
Authorized Shares
Redeemable preferred stock, authorized shares	0		4,000,000
Issued Shares
Redeemable preferred stock, issued shares	0		3,113,099
Outstanding Shares
Redeemable preferred stock, outstanding shares	0		3,113,099
Series B-1 preferred stock
Authorized Shares
Redeemable preferred stock, authorized shares	0		8,830,000
Issued Shares
Redeemable preferred stock, issued shares	0		5,461,802
Outstanding Shares
Redeemable preferred stock, outstanding shares	0		5,461,802
Series C preferred stock
Authorized Shares
Redeemable preferred stock, authorized shares	0		13,500,000
Issued Shares
Redeemable preferred stock, issued shares	0		8,753,547
Outstanding Shares
Redeemable preferred stock, outstanding shares	0		8,753,547
Common Stock
Issued Shares
Treasury Stock	(9,197)		(55,905)

Common stock and redeemable c74

Common stock and redeemable convertible preferred stock - Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 30, 2014	Jul. 27, 2015	Feb. 25, 2015	Mar. 31, 2014	Mar. 17, 2016	Feb. 25, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common stock warrants issued with Series B-1 redeemable preferred stock financing
Temporary equity related disclosures
Proceeds from exercises of warrants								$ 0
Number of outstanding warrants (in shares)							50,158
Common stock warrants issued with Series B-1 redeemable preferred stock financing | Common Stock
Temporary equity related disclosures
Exercise price of warrants (in dollars per share)							$ 0.0024
Number of shares issued upon exercise of warrants							286,968		520
Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Temporary equity related disclosures
Exercise price of warrants (in dollars per share)		$ 5
Proceeds from exercises of warrants		$ 5
Shares issued (in shares)		1,000,000
Redeemable convertible preferred stock financing | Series C preferred stock
Temporary equity related disclosures
Shares issued (in shares)	1,499,935		2,624,936	1,986,586		4,124,871
Proceeds from share issuance	$ 7.5		$ 13.1	$ 9.9		$ 20.6
Redeemable convertible preferred stock financing | Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Temporary equity related disclosures
Warrants issued (in shares)	749,967		1,197,218			1,947,185
Redeemable convertible preferred stock financing | Series B-1 preferred stock | Common stock warrants issued with Series B-1 redeemable preferred stock financing
Temporary equity related disclosures
Warrants issued (in shares)										389,474
Exercise price of warrants (in dollars per share)										$ 0.0024
Upon investor purchase of pro-rata share of stock | Redeemable convertible preferred stock financing | Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Temporary equity related disclosures
Exercise price of warrants (in dollars per share)	$ 5
Number of shares that can be purchased with each warrant	1
Number of purchased shares that entitle holder to receive a warrant	2
Subsequent event | Common stock warrants issued with Series B-1 redeemable preferred stock financing | Common Stock
Temporary equity related disclosures
Exercise price of warrants (in dollars per share)					$ 0.0024
Number of shares issued upon exercise of warrants					19,090

Common stock and redeemable c75

Common stock and redeemable convertible preferred stock - Reverse Stock Split, Authorized Shares, Public Offerings (Details) $ / shares in Units, $ in Millions	Jul. 28, 2015USD ($)$ / sharesshares	Jul. 10, 2015	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares
Public offerings and related transactions
Preferred stock, authorized shares	5,000,000		5,000,000	0
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001	$ 0.001
Common stock, authorized shares	100,000,000		100,000,000	35,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001	$ 0.001
Conversion of redeemable convertible preferred stock warrant into common stock warrant | Series C Warrants Issued with Senior Debt
Public offerings and related transactions
Warrants issued (in shares)	170,000
Conversion of redeemable convertible preferred stock warrant into common stock warrant | Common Stock Warrant
Public offerings and related transactions
Number of warrants converted into other warrants	70,833
Common Stock
Public offerings and related transactions
Reverse stock split ratio		0.4167
Common Stock | IPO
Public offerings and related transactions
Shares sold	5,520,000		5,520,000
Public offering price (in dollars per share) | $ / shares	$ 15
Net proceeds from issuance of stock | $	$ 75
Common Stock | Over-allotment option
Public offerings and related transactions
Shares sold	720,000
Common Stock | Conversion of redeemable convertible preferred stock into common stock | All series of redeemable convertible preferred stock
Public offerings and related transactions
Shares issued on conversion	9,217,983
Common Stock | Cashless exercise of redeemable convertible preferred stock warrant into common stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Public offerings and related transactions
Shares converted	947,185
Shares issued on conversion	78,926

Common stock and redeemable c76

Common stock and redeemable convertible preferred stock - Rights and Preferences of Preferred Stock (Details)	Nov. 01, 2017USD ($)installment$ / shares	Jul. 28, 2015shares	Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2015USD ($)
Temporary equity related disclosures
Fair value of warrants				$ 1,789,000
Redeemable preferred stock value				90,149,000
Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Temporary equity related disclosures
Fair value adjustment of warrants (reduction) increase			$ 1,698,000
Series C Warrants Issued with Series C Redeemable Preferred Stock Financing | Common Stock | Cashless exercise of redeemable convertible preferred stock warrant into common stock
Temporary equity related disclosures
Shares issued on conversion | shares		78,926
All series of redeemable convertible preferred stock | Common Stock | Conversion of redeemable convertible preferred stock into common stock
Temporary equity related disclosures
Shares issued on conversion | shares		9,217,983
Series A preferred stock
Temporary equity related disclosures
Original issue price (in dollars per share) | $ / shares			$ 5
Redeemable preferred stock value				1,068,000
Series C preferred stock
Temporary equity related disclosures
Original issue price (in dollars per share) | $ / shares			$ 5
Accretion to redemption value			$ 607,000	87,000	$ 78,000
Redeemable preferred stock value				42,131,000
Series B-1 preferred stock
Temporary equity related disclosures
Dividend accrual rate (as a percent)			8.00%
Original issue price (in dollars per share) | $ / shares			$ 5
Accretion to redemption value			$ 370,000	679,000	756,000
Redeemable preferred stock value				32,391,000
Series B preferred stock
Temporary equity related disclosures
Original issue price (in dollars per share) | $ / shares			$ 5
Accretion to redemption value			$ 192,000	352,000	$ 394,000
Redeemable preferred stock value				14,559,000
Redeemable convertible preferred stock financing | Series C preferred stock
Temporary equity related disclosures
Redeemable preferred stock value				6,108,000		$ 10,916,000
Stock issuance legal fees				57,000		78,000
Redeemable convertible preferred stock financing | Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Temporary equity related disclosures
Fair value of warrants				$ 1,335,000		$ 2,131,000
Forecast | Series C, Series B-1, and Series B preferred stock
Temporary equity related disclosures
Original issue price (in dollars per share) | $ / shares	$ 5
Number of installments for redemption | installment	3
Notice period for redemption	60 days
Redemption value (in dollars per share) | $ / shares	$ 5
Forecast | Series B-1 preferred stock
Temporary equity related disclosures
Minimum redemption value upon initial redemption date	$ 27,309,000
Forecast | Series B preferred stock
Temporary equity related disclosures
Minimum redemption value upon initial redemption date	15,565,000
Forecast Related To Issuances Through December 2014 | Series C preferred stock
Temporary equity related disclosures
Minimum redemption value upon initial redemption date	43,768,000
Forecast Related To Issuances Through IPO Date | Series C preferred stock
Temporary equity related disclosures
Minimum redemption value upon initial redemption date	$ 57,642,000

Stock options, restricted sto77

Stock options, restricted stock and performance stock options - Stock Options (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2015shares	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / shares	Dec. 31, 2013$ / shares	Jan. 01, 2016	Jul. 31, 2015shares	Nov. 30, 2009shares
Employee stock options | Performance based
Stock options, restricted stock and performance stock options
Vesting period		3 years
Stock options
Stock options, restricted stock and performance stock options
Expiration period		10 years
Expiration period of unexercised vested award after termination of employment		90 days
Weighted average key assumptions used in determining the fair value of options granted
Expected dividend yield (as a percent)		0.00%	0.00%	0.00%
Expected stock price volatility (as a percent)		60.00%	60.00%	60.00%
Weighted-average option fair value at grant (in dollars per share) | $ / shares		$ 9.723	$ 2.884	$ 1.305
Expected life		5 years	5 years	5 years
Stock options | Weighted average
Weighted average key assumptions used in determining the fair value of options granted
Risk-free interest rate (as a percent)		1.60%	1.77%	1.23%
Neos Therapeutics, Inc. 2009 Equity Plan
Stock options, restricted stock and performance stock options
Shares reserved for issuance under the plan							1,375,037
Neos Therapeutics, Inc. 2015 Stock Option and Incentive Plan
Stock options, restricted stock and performance stock options
Shares reserved for issuance under the plan						767,330
Increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)					5.00%
Stock option exercise price, minimum expressed as percentage of fair market value on grant date		100
Shares related to forfeited prior plan options transferred into shares available under current plan	1,389
Share of restricted stock transferred into shares available under current plan	9,197
Remaining shares available for grant	166,040	166,040

Stock options, restricted sto78

Stock options, restricted stock and performance stock options - Compensation Costs (Details) - Stock options - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based compensation
Unrecognized compensation cost	$ 7,500,000
Compensation cost not yet recognized, period for recognition	3 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	38,307	13,408	5,275
Proceeds received upon the exercise of outstanding stock options	$ 74,000	$ 4,000
Tax benefit from the exercise of stock options	0	0
General and administrative expense
Share-based compensation
Total compensation cost	$ 1,087,000	$ 120,000	$ 52,000

Stock options, restricted sto79

Stock options, restricted stock and performance stock options - Summary of Outstanding and Exercisable Options (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of number of outstanding and exercisable options and the activity
Outstanding at beginning of year (in shares)	511,775	326,062	175,866
Exercisable at beginning of year (in shares)	150,109	109,906
Granted (in shares)	883,537	237,486	187,267
Exercised (in shares)	(38,307)	(13,408)	(5,275)
Expired, forfeited or cancelled (in shares)	(4,722)	(38,365)	(31,796)
Outstanding at end of period (in shares)	1,352,283	511,775	326,062
Exercisable at end of period (in shares)	229,000	150,109	109,906
Summary of weighted-average exercise price of outstanding and exercisable options and the activity
Outstanding at beginning of year (in dollars per share)	$ 3.684	$ 1.797	$ 0.844
Exercisable at beginning of year (in dollars per share)	1.467	1
Granted (in dollars per share)	18.789	5.684	2.550
Exercised (in dollars per share)	1.928	0.324	0.305
Expired, forfeited or cancelled (in dollars per share)	2.547	1.206	1.208
Outstanding at end of period (in dollars per share)	13.607	3.684	1.797
Exercisable at end of period (in dollars per share)	$ 3.385	$ 1.467	$ 1
Summary of intrinsic value of outstanding and exercisable options and other information
Intrinsic value, outstanding options	$ 964	$ 2,883	$ 363
Intrinsic value, exercisable options	$ 2,504	$ 1,179	$ 210
Weighted average remaining contractual life of options outstanding	8 years 10 months 24 days
Weighted-average remaining contractual life of options exercisable	7 years 3 months 18 days
Minimum
Summary of weighted-average exercise price of outstanding and exercisable options and the activity
Granted (in dollars per share)	$ 9.32
Maximum
Summary of weighted-average exercise price of outstanding and exercisable options and the activity
Granted (in dollars per share)	$ 25.50

Stock options, restricted sto80

Stock options, restricted stock and performance stock options - Restricted Stock (Details) - Restricted stock - USD ($)	Oct. 16, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock options, restricted stock and performance stock options
Shares issued		0	0	149,244
Grant date fair value of shares issued (in dollars per share)				$ 2.550
Unrecognized compensation cost		$ 162,000
Compensation cost not yet recognized, period for recognition		1 year 9 months 18 days
Value of restricted stock awards settled	$ 658,000		$ 266,000
Tax benefit from settlement of vested restricted stock awards	$ 224,000		$ 90,000
Shares surrendered by holder to cover taxes associated with vesting	9,197
Current price (in dollars per share)	$ 18.54
Unvested restricted stock outstanding (in shares)		71,025	106,537	142,049	70,342
Weighted average fair value of nonvested restricted stock (in dollars per share)		$ 2.550	$ 2.550	$ 2.550	$ 0.510
General and administrative expense
Stock options, restricted stock and performance stock options
Stock compensation cost		$ 94,000	$ 90,000	$ 47,000
Minimum
Stock options, restricted stock and performance stock options
Vesting period		1 month
Maximum
Stock options, restricted stock and performance stock options
Vesting period		48 months
Immediate vesting
Stock options, restricted stock and performance stock options
Shares issued				7,195
Four equal tranches
Stock options, restricted stock and performance stock options
Vesting period				48 months
Shares issued				142,049

Stock options, restricted sto81

Stock options, restricted stock and performance stock options - Summary of Nonvested Restricted Stock (Details) - Restricted stock - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period	106,537	142,049	70,342
Shares granted			149,244
Shares vested	(35,512)	(35,512)	(21,633)
Shares forfeited			(55,904)
Nonvested, end of period	71,025	106,537	142,049
Nonvested, Weighted Average Grant Date Fair Value, Beginning of period (in dollars per share)	$ 2.550	$ 2.550	$ 0.510
Nonvested, Weighted Average Grant Date Fair Value, Granted (in dollars per share)			2.550
Nonvested, Weighted Average Grant Date Fair Value, Vested (in dollars per share)	2.550	2.550	1.499
Nonvested, Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)			0.390
Nonvested, Weighted Average Grant Date Fair Value, End of period (in dollars per share)	$ 2.550	$ 2.550	$ 2.550

Treasury stock (Details)

Treasury stock (Details) - $ / shares	Oct. 16, 2015	Feb. 19, 2015	Dec. 31, 2013
Treasury stock disclosures
Treasury shares purchased			55,905
Original purchase price of treasury stock (in dollars per share)			$ 0.002
Cancellation of treasury stock		55,905
Restricted stock
Treasury stock disclosures
Shares surrendered by holder to cover taxes associated with vesting	9,197

Commitments and contingencies -

Commitments and contingencies - Defined Contribution Plans (Details)	12 Months Ended
	Dec. 31, 2015USD ($)age	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Defined Contribution Plans
Maximum employee annual contribution (as a percent)	50.00%
Maximum employee annual contribution	$ 17,500
Minimum employee age requirement to make catch up contributions | age	50
Maximum catch up contributions allowed to employees who are 50 or older	$ 5,500
Employer's match of the eligible percentage of employee contributions (as a percent)		50.00%
Employer's match of the next 2% of an employee's salary (as a percent)	0.50%
Percentage of employee's second tier contribution, matched 1/2% by employer	2.00%
Maximum total matching contribution by employer (as a percent)	4.00%
Expense on defined contribution plans	$ 186,000	$ 82,000	$ 91,000
Maximum
Defined Contribution Plans
Percentage of eligible compensation, matched by employer (as a percent)	3.00%	6.00%

Commitments and contingencies84

Commitments and contingencies - Operating Lease, Cash Incentive Bonus Plan (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Future minimum operating lease payments
2,016	$ 1,003,000	$ 1,003,000
2,017	1,102,000	1,102,000
2,018	1,105,000	1,105,000
2,019	1,107,000	1,107,000
2,020	1,161,000	1,161,000
Thereafter	4,274,000	4,274,000
Future minimum lease payments	9,752,000	9,752,000
Deferred rent balance	$ 1,166,000	1,166,000	$ 1,189,000
Rent expense, excluding share of operating expenses		884,000	896,000	$ 879,000
Compensation expense under bonus plan		552,000
Blue Bell, Pennsylvania
Operating lease:
Term of operating lease	60 months
Grand Prairie
Future minimum operating lease payments
Rent expense, share of operating expenses		$ 237,000	$ 251,000	$ 208,000

License agreements (Details)

License agreements (Details) - Shire LLC - Maximum $ in Millions	Jul. 23, 2014USD ($)
License agreements disclosure
Non refundable license fee to be less than $1 million	$ 1
Maximum period for payment of license fee after regulatory approval by FDA	30 days

Discontinued Operations (Detail

Discontinued Operations (Details)	12 Months Ended
	Dec. 31, 2013USD ($)
Discontinued operations
Impairment of intangible assets	$ 544,000
Net loss from discontinued operations	(437,000)
Discontinued Operations [Member]
Discontinued operations
Revenue	943,000
Direct Costs	836,000
Impairment of intangible assets	544,000
Net loss from discontinued operations	$ (437,000)

Related party transactions (Det

Related party transactions (Details)	Jul. 21, 2014USD ($)	Jun. 28, 2015	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)item	Mar. 31, 2014USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)
Entity affiliated with Company's Chairman of the board of directors
Related party transactions disclosures
Expenses from transactions with related party			$ 0	$ 112,000	$ 499,000
10% subordinated note payable | Essex Capital Corporation, as Investor
Related party transactions disclosures
Aggregate principal amount			$ 5,935,000	$ 5,935,000				$ 5,900,000
Payment for legal settlement	$ 128,000
Interest rate (as a percent)			10.00%
Debt Instrument, Reduced Interest Rate During Period Per Amendment		6.00%
Capital leases
Related party transactions disclosures
Maximum amount authorized under sale and leaseback transaction							$ 6,500,000
Number of transactions | item					4
Sale and leaseback amount due					$ 5,500,000
Sale and leaseback additional amount raised						$ 795,000
Essex Capital Corporation | Third Party
Related party transactions disclosures
Payment for legal settlement made by related party to third party	$ 256,000

Selected Quarterly Financial 88

Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selected Quarterly Financial Information
Net Sales	$ 1,659	$ 221	$ 1,484	$ 428	$ 436	$ (25)	$ 55	$ 292	$ 3,792	$ 758	$ 1,044
Gross loss	(55)	(858)	(175)	(667)	(693)	(807)	(583)	(513)	(1,755)	(2,596)	(1,490)
Net loss	(9,104)	(9,368)	(5,753)	(6,556)	(4,857)	(5,239)	(5,588)	(5,165)	(30,781)	(20,849)	(19,037)
Preferred Stock Accretion to Redemption Value		(99)	(586)	(484)	(268)	(268)	(265)	(317)	(1,169)	(1,118)	(1,227)
Preferred Stock Dividends		(138)	(544)	(539)	(551)	(551)	(544)	(539)	(1,221)	(2,185)	(2,185)
Net loss attributable to common stock	$ (9,104)	$ (9,605)	$ (6,883)	$ (7,579)	$ (5,676)	$ (6,058)	$ (6,397)	$ (6,021)	$ (33,171)	$ (24,152)	$ (22,449)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	15,933,315	12,403,182	887,397	885,237	881,309	878,929	873,060	871,282	7,581,881	876,318	788,964
Net loss per share of common stock, basic and diluted (1)	$ (0.57)	$ (0.77)	$ (7.76)	$ (8.56)	$ (6.44)	$ (6.89)	$ (7.33)	$ (6.91)	$ (4.38)	$ (27.56)	$ (28.45)

Selected Quarterly Financial 89

Selected Quarterly Financial Data - Explanatory Information (Details) $ / shares in Units, $ in Millions	Jul. 28, 2015$ / sharesshares	Jul. 10, 2015	Jul. 27, 2015USD ($)$ / sharesshares	Dec. 31, 2015$ / sharesshares
Series C preferred stock
Quarterly Financial Information [Line Items]
Public offering price (in dollars per share) | $ / shares				$ 5
Series C preferred stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing
Quarterly Financial Information [Line Items]
Number of shares issued upon exercise of warrants			1,000,000
Exercise price of warrants (in dollars per share) | $ / shares			$ 5
Proceeds from exercise of warrants (in dollars) | $			$ 5
Common Stock
Quarterly Financial Information [Line Items]
Reverse stock split ratio		0.4167
Common Stock | Series C Warrants Issued with Series C Redeemable Preferred Stock Financing | Cashless exercise of redeemable convertible preferred stock warrant into common stock
Quarterly Financial Information [Line Items]
Shares issued on conversion	78,926
Common Stock | All series of redeemable convertible preferred stock | Conversion of redeemable convertible preferred stock into common stock
Quarterly Financial Information [Line Items]
Shares issued on conversion	9,217,983
Common Stock | IPO
Quarterly Financial Information [Line Items]
Net proceeds from issuance of common stock (in shares)	5,520,000			5,520,000
Public offering price (in dollars per share) | $ / shares	$ 15
Common Stock | Over-allotment option
Quarterly Financial Information [Line Items]
Net proceeds from issuance of common stock (in shares)	720,000

Subsequent events (Details)

Subsequent events (Details) - Common Stock - Common stock warrants issued with Series B-1 redeemable preferred stock financing - $ / shares	3 Months Ended	12 Months Ended
	Mar. 17, 2016	Dec. 31, 2015	Dec. 31, 2013
Subsequent events disclosures
Number of shares issued upon exercise of warrants		286,968	520
Exercise price of warrants (in dollars per share)		$ 0.0024
Subsequent event
Subsequent events disclosures
Number of shares issued upon exercise of warrants	19,090
Exercise price of warrants (in dollars per share)	$ 0.0024

Subsequent events (Details 2)

Subsequent events (Details 2) - Neos Therapeutics, Inc. 2015 Stock Option and Incentive Plan - shares	Jan. 01, 2016	Jul. 31, 2015
Subsequent events disclosures
Shares reserved for issuance under the plan		767,330
Subsequent event
Subsequent events disclosures
Increase in number of shares reserved and available for issuance	800,797
Shares reserved for issuance under the plan	966,837

Subsequent events (Details 3)

Subsequent events (Details 3) $ in Millions	Feb. 26, 2016USD ($)
Subsequent event | Adzenyas XR-ODT | Maximum
Subsequent events disclosures
Lump sum payment of non-refundable license fee	$ 1

Schedule II - Valuation and Q93

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Allowance for chargebacks
Movement in valuation and qualifying accounts
Balance at beginning of period	$ 190
Additions charged to costs and expenses	5,359	$ 202
Deductions	(4,609)	(12)
Balance at end of period	940	190
Allowance for cash discounts
Movement in valuation and qualifying accounts
Balance at beginning of period	14
Additions charged to costs and expenses	194	18
Deductions	(109)	(4)
Balance at end of period	99	14
Reserve for wholesaler fees
Movement in valuation and qualifying accounts
Balance at beginning of period	117
Additions charged to costs and expenses	914	122
Deductions	(670)	(5)
Balance at end of period	361	117
Reserve for returns
Movement in valuation and qualifying accounts
Balance at beginning of period	212
Additions charged to costs and expenses	242	212
Deductions	(25)
Balance at end of period	429	212
Government rebates
Movement in valuation and qualifying accounts
Balance at beginning of period	9
Additions charged to costs and expenses	103	9
Deductions	(2)
Balance at end of period	$ 110	$ 9